UCSF HELEN DILLER FAMILY COMPREHENSIVE CANCER CENTER

UCSF HELEN DILLER 

FAMILY COMPREHENSIVE 

CANCER CENTER 

American Society of Clinical Oncology Annual Meeting 

June 3-7, 2016 

Chicago, IL 

UCSF Presentation Brochure

Committed to Advancing 

Development of Improved 

Cancer Therapies, Imaging 

Modalities, and Biomarkers 

As president of the UCSF Helen Diller Family Comprehensive Cancer 

Center, one of my key priorities is to initiate and advance programs 

that are developing new anticancer drugs making significant impact 

on helping cancer patients live longer and better lives. I recognize this 

goal is best accomplished by working in partnership with the broader 

life science industry. This searchable abstract book of UCSF research 

presented at ASCO is a resource for potential partners interested in 

identifying world-class faculty engaged in clinical oncology research. 

As an NCI-designated comprehensive cancer center, UCSF is 

recognized for our outstanding science, extensive resources, depth 

and breadth of our research in basic, clinical, and/or population 

sciences, as well as cutting edge research that bridges these 

scientific areas. Practically this means that our clinicians and basic 

scientists work closely together to (1) identify, develop and optimize 

novel therapeutics for biological efficacy and clinical utility, (2) assess 

tumor status and responsiveness to current therapies, (3) develop 

biomarkers for patient stratification and therapeutic response and (4) 

advance supportive care options to mitigate the toxicities associated 

with chemotherapy. 

Alan Ashworth, PhD, FRS 

President, UCSF Helen Diller 

Family Comprehensive 

Cancer Center 

Senior Vice President 

for Cancer Services, 

UCSF Health 

As is evident from the breadth and depth the research being 

presented at this year’s ASCO, UCSF is home to many of world’s 

finest oncology scientists and clinicians. I invite you learn more about 

our work and expertise by reaching out to our faculty. If you have any 

additional questions or need any assistance with your outreach, please 

contact the Director of Strategic Alliances for the Cancer Center: 

Cammie Edwards ( ). 

Wishing you a very productive meeting and we look forward to 

future discussions and collaborations. 

Professor of Medicine, 

Division of Hematology/ 

Oncology, Department 

of Medicine 

Alan Ashworth, PhD, FRS 

President, UCSF Helen Diller Family Comprehensive Cancer Center 

2

HDFCCC Overview 

A Designated NCI Comprehensive 

Cancer Center Since 1999 

The “comprehensive” designation—NCI’s highest ranking, awarded only 

after a rigorous evaluation process—recognizes UCSF’s excellence in 

basic research, clinical research, population based research, outreach and 

education, and our ability to integrate these diverse research approaches to 

cancer and turn them into clinical practice. 

Our Success is Driven by Our Faculty 

HDFCCC Membership: 397 Members & Associate Members 

2 Nobel Laureates 

3 Albert Lasker Award winners 

8 Howard Hughes Medical Investigators 

13 Members of the National Academy of Sciences 

20 Members of the Institute of Medicine 

18 Fellows of the American Academy of Arts and Sciences 

4 Fellows of the Royal Society 

3


Working Together Advancing the 

Understanding and Treatment of Cancer 

Multi-Disciplinary Research Programs 

• Breast Oncology 

• Cancer Control 

• Cancer Genetics 

• Cancer, Immunity, and Microenvironment 

• Developmental Therapeutics 

• Hematopoietic Malignancies 

• Neurologic Oncology 

• Pediatric Malignancies 

• Prostate Cancer 

• Tobacco Control 

Multi-Disciplinary Clinical Programs 

• GU Oncology (non Prostate) 

• GI (includes Pancreas Cancer) 

• Thoracic Oncology 

• Cutaneous Oncology 

• Head and Neck Cancer 

• Sarcoma 

• Endocrine 

• Gynecologic Oncology 

• Breast Oncology 

• Prostate Cancer 

Key Initiatives 

• Cancer Imaging 

• Cancer Immunotherapeutics 

• Global Oncology 

• Center for BRCA Research 

• UCSF 500 

• Target Validation Initiative 

Advancing the Next Wave of Cancer Treatment Breakthroughs 

Whether it is pioneering novel clinical trial designs, discovering, developing and bringing to 

the clinic revolutionary treatments such as immunotherapies or harnessing the power of big 

data to drive faster, personalized and more effective cures, UCSF leads in advancing the next 

wave of cancer treatment breakthroughs. With a culture of collaboration, a commitment to 

excellence and access to cutting-edge laboratory and clinical technologies, UCSF faculty 

work tirelessly to improve clinical outcomes for cancer patients everywhere.


Core Capabilities 

Supporting Our Programs 

• Biostatistics 

• Clinical Research Support 

• Genome Analysis 

• Laboratory for Cell Analysis 

• Immunohistochemistry & Molecular Pathology 

• Mouse Pathology 

• Preclinical Therapeutic Testing 

• Bio-specimen Banking 

• Tobacco Biomarkers 

• Bioinformatics 

• Computational Biology 

Approximately one-quarter of the 

University’s ~2,200 full-time faculty 

members work in cancer research or 

cancer care. 

UCSF consistently ranks among 

the top U.S. biomedical research 

organizations in cancer-specific 

federal funding. In 2015, UCSF 

received more than $85M from the 

National Cancer Institute. 

5

Partnering with 

UCSF HDFCCC 

UCSF faculty have a long history of working with industry 

partners translating discoveries into products that ultimately 

improve patient care. We are experienced in establishing and 

executing on a wide range of successful partnerships. If you are 

interested in learning more about working with the HDFCCC 

and its faculty, please contact: 

Cammie Edwards, PhD 

Director of Strategic Alliances, HDFCCC 

• On average, UCSF has 200-300 new invention disclosures per year 

• An estimated 90 life science start-up companies have been spawned 

from the University’s labs, including Genentech, Chiron, and Intellikine 

• Included among UCSF patents are top revenue producers, such as 

- Hepatitis B vaccine 

- Bovine growth hormone 

- Barrier repair lipids 

- Yeast expression vector 

- Magnetic resonance imaging 

UCSF IN THE NEWS (Click on title to read story) 

New Cancer Immunotherapy Clinic Offers Unique Studies of Promising Treatments 

https://www.ucsf.edu/news/2016/04/402411/new-cancer-immunotherapy-clinic-offers-unique-studies-promising-treatments 

New UCSF Center for BRCA Research Expands Care for Increased Cancer Risk 

http://cancer.ucsf.edu/news/2016/04/19/new-ucsf-center-for-brca-research-expands-care-for-increased-cancer-risk.7470 

Better Survival for Colon Cancer Patients with Left-Sided Tumors 

Location Matters, Says Study to Be Presented at ASCO 

http://cancer.ucsf.edu/news/2016/05/18/better-survival-for-colon-cancer-patients-with-left-sided-tumors.7638 

Berger, Bluestone Named to White House Cancer Moonshot Expert Panel 

http://cancer.ucsf.edu/news/2016/04/06/berger-bluestone-named-to-white-house-cancer-moonshot-expert-panel.7418 

Read interview with UCSF’s Dr. Michael Korn on 

“When to Suspect Germline Abnormality from Genetic Testing Results” 

- ASCO daily news [ http://am.asco.org/dn ] | print version: June 6, 2016

Presentations 

Presentations 

View full abstracts on line at: 

http://am.asco.org/abstracts 

*UCSF authors in bold 

Updated data from a phase II dose finding trial of single agent 

isatuximab (SAR650984, anti-CD38 mAb) in relapsed/refractory 

multiple myeloma (RRMM). 

Authors*: Joshua Ryan Richter, Thomas G. Martin, Ravi Vij, Craig Cole, Djordje Atanackovic, Jeffrey A. Zonder, 

Jonathan L. Kaufman, Joseph Mikhael, William Bensinger, Meletios A. Dimopoulos, Todd M. Zimmerman, 

Nikoletta Lendvai, Parameswaran Hari, Enrique M. Ocio, Cristina Gasparetto, Shaji Kumar, Corina Oprea, 

Eric Charpentier, Stephen Anthony Strickland, Jesus San Miguel 

Abstract #: 8005 

Presentation Date/Time: Friday, June 3: 3:00 - 6:00 PM 

Location: E354b 

Session: Hematologic Malignancies - Plasma Cell Dyscrasias 

Citation: J Clin Oncol 34, 2016 (suppl; abstr 8005) 

Martin Research Interests: A leading expert in hematology-oncology, Dr. Thomas Martin is the associate 

director of the Myeloma Institute and director of the Unrelated Donor Transplantation Program for adults 

at UCSF Medical Center. He is also the clinical research directory of hematologic malignancies, or blood 

cancers, at the UCSF Helen Diller Family Comprehensive Cancer Center. His research interests include 

developing treatments for myeloma and leukemia as well as expanding the use of bone marrow transplants. 

He has a special interest in umbilical cord blood transplants and is involved in efforts to improve the 

outcomes following unrelated donor transplants. 

http://cancer.ucsf.edu/research/multiple-myeloma/mmti/mmti_team#martin 


7

Presentations 

Plasma asparaginase activity and asparagine depletion in patients 

with acute lymphoblastic leukemia (ALL) treated with pegaspargase 

(SS-PEGE. coli L-asparaginase): Results from Children’s Oncology 

Group (COG) study AALL07P4. 

Authors*: Reuven J. Schore, Meenakshi Devidas, Archie Bleyer, Gregory H. Reaman, Naomi J. Winick, 

Mignon L. Loh, Elizabeth A. Raetz, William L. Carroll, Stephen Hunger, Anne L. Angiolillo 



Location: S504 

Session: Pediatric Oncology I 


__________________________________________________________________________ 

MONARCH1: Results from a phase II study of abemaciclib, a CDK4 

and CDK6 inhibitor, as monotherapy, in patients with HR+/HER2- 

breast cancer, after chemotherapy for advanced disease. 

Authors*: Maura N. Dickler, Sara M. Tolaney, Hope S. Rugo, Javier Cortes, Véronique Diéras, Debra A. Patt, 

Hans Wildiers, Martin Frenzel, Andrew Koustenis, Jose Baselga 



Location: Hall D1 

Session: Future Directions in Breast Cancer Treatment: New Drugs, New Markers 


Rugo Research Interests: Dr. Rugo, Director of Breast Oncology & Clinical Trials Education, is PI on multiple 

clinical trials focusing on combining novel targeted therapeutics to improve the treatment of both early & late 

stage breast cancer (BC). She also works on studies to improve supportive care for early & late stage BC 

patients, including with UCSF’s Advanced Breast Cancer Program. Dr. Rugo has numerous collaborations with 

large academic medical centers & consortia in order to expand the novel therapies available to patients. She 

was the director of the 2016 ASCO Breast Cancer Education Committee meeting, is a member of the Alliance 

& is a founding member of the Breast Cancer Research Consortium where she co-leads the triple negative 

working group. She is on the novel agents committee for the neoadjuvant multi-center I SPY2 trial. At UCSF, 

Dr. Rugo runs the Breast Forum, a bimonthly educational session for breast cancer patients, families & friends 

from throughout the bay area. 

http://cancer.ucsf.edu/people/profiles/rugo_hope.3648 


8

Presentations 

Phase II trials of cetuximab plus combined modality therapy (CMT) in 

squamous cell carcinoma of the anal canal (SCCAC) with and without 

human immunodeficiency virus (HIV) infection. 

Authors*: Madhur Garg, Fengmin Zhao, Jeannette Y. Lee, Joseph A. Sparano, Joel Palefsky, David H. Henry, 

William Wachsman, Lakshmi Rajdev, David Michael Aboulafia, Lee Ratner, Lisa A. Kachnic, Edith P. Mitchell, 

Adedayo A. Onitilo, Ronald T. Mitsuyasu, Al Bowen Benson 


Presentation Date/Time: Saturday, June 4: 8:00 - 11:30 AM 

Location: Hall A Poster Board # 219 

Session: Gastrointestinal (Colorectal) Cancer 


__________________________________________________________________________ 

Blood-based biomarkers in patients (pts) with metastatic colorectal 

cancer (mCRC) treated with FOLFOX or FOLFIRI plus bevacizumab 

(Bev), cetuximab (Cetux), or bev plus Cetux: Results from CALGB 

80405 (Alliance). 

Authors*: Andrew B. Nixon, Alexander Sibley, Ace Joseph Hatch, Yingmiao Liu, Chen Jiang, Flora Mulkey, 

Mark D. Starr, John C. Brady, Donna Niedzwiecki, Federico Innocenti, Alan P. Venook, Howard S. Hochster, 

Heinz-Josef Lenz, Bert H. O’Neil, Kouros Owzar, Herbert Hurwitz 



Location: Hall A, Poster Board #294 



Venook Research Interests: Dr. Alan Venook is a nationally renowned expert in colorectal and liver cancers at 

the UCSF Helen Diller Family Comprehensive Cancer Center. He is highly regarded for his expertise in the 

effective use of the newest approaches and therapies to the treatment of colorectal cancer, as well treating 

primary and metastatic tumors to the liver. Dr. Venook has chaired and/or authored six major studies within 

the cooperative groups and he now Chairs the GI Committee of the Alliance for Clinical Trials in Oncology 

(formerly CALGB.) 

http://cancer.ucsf.edu/people/profiles/venook_alan.3698 


9

Presentations 

A phase 2 study of galunisertib, a novel transforming growth factorbeta 

(TGF-β) receptor I kinase inhibitor, in patients with advanced 

hepatocellular carcinoma (HCC) and low serum alpha fetoprotein (AFP). 

Authors*: Sandrine J. Faivre, Armando Santoro, Edward Gane, Robin Kate Kelley, I Ollivier Hourmand, 

Eric Assenat, Ivelina Gueorguieva, Ann Cleverly, Durisala Desaiah, Michael M. F. Lahn, Eric Raymond, 

Karim A. Benhadji, Gianluigi Giannelli 




Session: Gastrointestinal (Noncolorectal) Cancer 


__________________________________________________________________________ 

A randomized, double-blinded, placebo-controlled phase II trial of 

gemcitabine (gem) plus nab-paclitaxel (nab-P) plus apatorsen (A) or 

placebo (Pl) in patients (pts) with metastatic pancreatic cancer (mPC): 

The RAINIER trial. 

Authors*: Andrew H. Ko, Patrick Brian Murphy, James D. Peyton, Dianna Shipley, Ahmed Al-Hazzouri, 

Francisco Antonio Rodriguez, Mark Sanders Womack, Henry Q. Xiong, David Michael Waterhouse, 

Margaret A. Tempero, Shuangli Guo, Cassie Michelle Lane, Christopher Earwood, Laura M. DeBusk, 

Johanna C. Bendell 




Poster Session: Gastrointestinal (Noncolorectal) Cancer 


Ko Research Interests: My work focuses on gastrointestinal malignancies, where I have developed and 

led multiple clinical trials, both within UCSF and across multiple sites. I am interested in the development 

and evaluation of new therapeutic agents ranging from novel cytotoxics to molecular targeted agents to 

immunotherapies, with a particular emphasis in pancreatic cancer. This work entails collaborating with 

laboratory-based investigators on translational science to identify individual patient/tumor characteristics that 

influence prognosis and response to specific therapies. I lead the UCSF site committee for gastrointestinal 

cancer-specific clinical trial development and serve as chair of the scientific Protocol Review Committee. 

Nationally, I sit on the editorial board for multiple peer-reviewed oncology journals, am a member of NCI’s 

Pancreatic Cancer Task Force and the NCCN Pancreatic Cancer guidelines committee. 

http://cancer.ucsf.edu/people/profiles/ko_andrew.3444 


10

Presentations 

CRS-207 immunotherapy expressing mesothelin, combined with 

chemotherapy as treatment for malignant pleural mesothelioma (MPM). 

Authors*: Raffit Hassan, Evan W. Alley, Hedy L. Kindler, Scott Joseph Antonia, Thierry Marie Jahan, 

Somayeh Honarmand, Katherine McDougall, Chan C. Whiting, Nitya Nair, Amanda Enstrom, Ed Lemmens, 

Takahiro Tsujikawa, Sushil Kumar, Lisa M Coussens, Aimee Murphy, Anish Thomas, Dirk G. Brockstedt 




Session: Lung Cancer - Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers 


__________________________________________________________________________ 

Pembrolizumab (pembro) plus chemotherapy as front-line therapy for 

advanced NSCLC: KEYNOTE-021 cohorts A-C. 

Authors*: Shirish M. Gadgeel, James Stevenson, Corey J. Langer, Leena Gandhi, Hossein Borghaei, 

Amita Patnaik, Liza Cosca Villaruz, Matthew A. Gubens, Ralph J. Hauke, James Chih-Hsin Yang, 

Lecia V. Sequist, Robert D. Bachman, Joy Yang Ge, Harry Raftopoulos, Vassiliki Papadimitrakopoulou 




Session: Lung Cancer - Non-Small Cell Metastatic 


Gubens Research Interests: Matthew Gubens is a thoracic oncologist who treats patients with lung cancer, 

mesothelioma and other thoracic malignancies, including thymoma and thymic carcinoma, which are rare 

tumors of the mediastinum. His research involves designing clinical trials to study new compounds and 

treatment strategies in lung cancer. He and his colleagues have a special interest in translational medicine, 

and are actively working to translate laboratory-based findings to the clinic, especially for patients with 

epidermal growth factor receptor (EGFR) mutations. The group is also active in trials evaluating new 

immunotherapy approaches in thoracic malignancies. Dr. Gubens is a member of the American Society of 

Clinical Oncology, the International Association for the Study of Lung Cancer and the International Thymic 

Malignancy Interest Group. 

http://profiles.ucsf.edu/matthew.gubens 


11

Presentations 

Pembrolizumab vs docetaxel for previously treated advanced NSCLC 

with a PD-L1 tumor proportion score (TPS) 1%-49%: Results from 

KEYNOTE-010. 

Authors*: Edward B. Garon, Roy S. Herbst, Dong-Wan Kim, Enriqueta Felip, Jose Luis Perez-Gracia, Ji-Youn Han, 

Julian R. Molina, Joo-Hang Kim, Catherine Dubos Arvis, Myung-Ju Ahn, Margarita Majem, Mary J. Fidler, 

Matthew A. Gubens, Gilberto Castro, Marcelo Garrido, Yue Shentu, Ellie Im, Gregory M. Lubiniecki, Paul Baas 

















12

Presentations 

Long-term OS for patients with advanced NSCLC enrolled in the 

KEYNOTE-001 study of pembrolizumab (pembro). 

Authors*: Rina Hui, Leena Gandhi, Enric Carcereny Costa, Enriqueta Felip, Myung-Ju Ahn, Joseph Paul Eder, 

Ani Sarkis Balmanoukian, Natasha B. Leighl, Charu Aggarwal, Leora Horn, Amita Patnaik, 

Gary William Middleton, Matthew A. Gubens, Matthew David Hellmann, Jean-Charles Soria, 

Suresh S. Ramalingam, Gregory M. Lubiniecki, Jin Zhang, Bilal Piperdi, Edward B. Garon 

















13

Presentations 

Phase I/II study of pembrolizumab (pembro) plus ipilimumab (ipi) as 

second-line therapy for NSCLC: KEYNOTE-021 cohorts D and H. 

Authors*: Matthew A. Gubens, Lecia V. Sequist, James Stevenson, Steven Francis Powell, Liza Cosca 

Villaruz, Shirish M. Gadgeel, Corey J. Langer, Amita Patnaik, Hossein Borghaei, Shadia Ibrahim Jalal, Joseph 

Fiore, Joy Yang Ge, Harry Raftopoulos, Leena Gandhi 




Poster Session: Lung Cancer - Non-Small Cell Metastatic 













14

Presentations 

Randomized phase 2 study of the safety, efficacy, and immune 

response of GVAX pancreas (with cyclophosphamide) and CRS- 

207 with or without nivolumab in patients with previously treated 

metastatic pancreatic adenocarcinoma (STELLAR). 

Authors*: Dung T. Le, Todd S. Crocenzi, Jennifer N. Uram, Eric R. Lutz, Daniel A. Laheru, Elizabeth A. Sugar, 

Robert H. Vonderheide, George A. Fisher, Andrew H. Ko, Aimee Murphy, Katherine McDougall, Sandy Ferber, 

Dirk G. Brockstedt, Elizabeth M. Jaffee 

Abstract #: TPS4153 


Location: Hall A, Poster Board #134a 


Citation: J Clin Oncol 34, 2016 (suppl; abstr TPS4153) 












15

Presentations 

Amethyst NSCLC trial: Phase 2, parallel-arm study of receptor 

tyrosine kinase (RTK) inhibitor, MGCD265, in patients (pts) with 

advanced or metastatic non-small cell lung cancer (NSCLC) 

with activating genetic alterations in mesenchymal-epithelial 

transition factor (MET). 

Authors*: Igor I. Rybkin, Ebenezer A. Kio, Ashiq Masood, Merrill Kingman Shum, Balazs Halmos, 

Collin M. Blakely, Keith D. Eaton, Neelesh Sharma, John J. Nemunaitis, Steven J. Saccaro, Yanis Boumber, 

Raul R. Mena, Hamid R. Mirshahidi, Pasi A. Janne, James Christensen, Richard C. Chao, 

Vanessa Roberts Tassell, Demiana Faltaos, Marshall T. Schreeder 






__________________________________________________________________________ 

TIGER-3: A phase 3 multinational open-label randomized study of 

rociletinib vs investigator-choice chemotherapy in patients (pts) with 

epidermal growth factor receptor mutant-positive (EGFRm) non-small 

cell lung cancer (NSCLC) progressing on prior EGFR tyrosine kinase 

inhibitor (TKI) therapy and doublet chemotherapy. 

Authors*: James Chih-Hsin Yang, Sanjay Popat, Silvia Novello, Harry J.M. Groen, Maurice Perol, 

Enriqueta Felip, Frank Griesinger, Karen L. Reckamp, Jong-Seok Lee, Egbert F. Smit, Collin M. Blakely, 

Wallace L. Akerley, Young-Chul Kim, Lyudmila Bazhenova, Raffaele Califano, Richard Delmar Hall, 

Panayiotis Georgiou, Jeffrey D. Isaacson, Tony Golsorkhi, Heather A. Wakelee 



Location: Hall A, Poster Board 425b 




16

Presentations 

Genomic Profiling to distinguish poorly differentiated neuroendocrine 

carcinomas arising in different sites. 

Authors*: Emily K. Bergsland, Ritu Roy, Phil Stephens, Jeffrey S. Ross, Mark Bailey, Adam Olshen 




Poster Session: Gastrointestinal (Noncolorectal) Cancer 


Bergsland Research Interests: My research is focused on the development and testing of novel, biologically 

based therapies for gastrointestinal malignancies, with an emphasis on neuroendocrine tumors (NETs). I am 

co-chair of the Neuroendocrine Tumor Task Force of the NCI Gastrointestinal Steering Committee, a NCCN 

Neuroendocrine Tumors Guidelines Panel member, Board of Directors member for NANETS, and co-chair 

of the 8th edition AJCC Expert Panel on staging for NETs. I am study chair for ALLIANCE A021202 (an 

ongoing randomized Phase II trial of pazopanib vs. placebo in patients with progressive carcinoid tumors). 

My current research focuses on data from three completed investigator-initiated Phase II clinical trials in NETs 

(a. FOLFOX/bevacizumab, b. everolimus plus erlotinib, and c. axitinib), fostering several collaborations with 

laboratory-based colleagues, and taking advantage of a fully annotated outcomes database (established in 

2010 and encompassing 600+ NET patients treated at UCSF since 2004). 

http://cancer.ucsf.edu/gi/emily-bergsland 

__________________________________________________________________________ 

Head and Neck Cancer Updates from the American Society for 

Radiation Oncology 

Authors*: Sue Sun Yom 

Abstract #: 


Location: S100bc 

Education Session: Best of the Rest: Top Abstracts on Head and Neck Cancer from 

the 2015-2016 Oncology Meetings 

Citation: 

Yom Research Interests: Dr. Yom is an expert in head and neck, thoracic, and skin cancers and conducts 

research in quality of life and supportive care, patient-oriented decision making, and combinations of novel 

targeted therapies and immunotherapy with radiation therapy. She is the principal investigator of HN002, 

a national trial in de-intensified therapy for HPV+ oropharyngeal cancer. She serves on several national 

panels developing guidelines for appropriate care of head and neck cancers. 

http://profiles.ucsf.edu/sue.yom 


17

Presentations 

Comprehensive mutation analysis in NRG Oncology/RTOG 9813: 

A phase III trial of RT + TMZ vs RT + nu for anaplastic astrocytoma 

and mixed anaplastic oligoastrocytoma (Astrocytoma Dominant). 

Authors*: Erica Hlavin Bell, Joseph P McElroy, Jessica Fleming, Cynthia Dawn Timmers, Arup R Chakraborty, 

Andrea L Salavaggione, Susan Marina Chang, Kenneth D. Aldape, David Brachman, Helen Alice Shih, 

Peixin Zhang, Minesh P. Mehta, Arnab Chakravarti 


Presentation Date/Time: Saturday, June 4: 1:00 - 4:30 PM 

Location: Hall A, Poster Board # 205 

Session: Central Nervous System Tumors 


Chang Research Interests: My research interest is in the development of novel therapies for patients with brain 

tumors, as well as the assessment of novel imaging biomarkers in the management of patients. My research 

seeks to integrate advances in physiologic and metabolic imaging with tissue biomarkers in order to optimize 

the management of patients with glioblastoma (GBM). My clinical research evaluates a wide spectrum of 

therapeutic interventions that span chemotherapy, targeted agents, immunotherapy and convection enhanced 

delivery of novel agents. I am the site PI of an NIH-funded adult brain tumor consortium and am a member 

of the Brain Malignancy Steering Committee and the Developmental Therapeutics Study Section at the NIH. I 

am the program leader for the Neuro-Oncology Program at the HDFCCC. I am the clinical co-PI for the UCSF 

Brain Tumor SPORE and a co-Leader of a SPORE Project evaluating the role of physiologic imaging in the 

determination of malignant progression of low-grade glioma. 

http://cancer.ucsf.edu/people/profiles/chang_susan.3565 


18

Presentations 

Validating RNAseq-signatures of vorinostat (VOR) sensitivity and 

resistance in patients with newly diagnosed glioblastoma (GBM) 

treated with VOR, temozolomide and radiation therapy in Alliance 

N0874/ABTC-0902. 

Authors*: S. Keith Anderson, C. Ryan Miller, Jann Nagina Sarkaria, Kurt A. Jaeckle, Jan C. Buckner, 

Keith L. Ligon, Karla V. Ballman, Dennis Frederic Moore, David Schiff, Manmeet Singh Ahluwalia, 

Eudocia Quant Lee, Laura E. Horvath, Elizabeth Robins Gerstner, Glenn Jay Lesser, Michael Prados, 

Stuart A. Grossman, Caterina Giannini, Patrick Y. Wen, Evanthia Galanis 






Prados Research Interests: Dr. Prados is a world-recognized Neuro-oncology expert. He led the Adult 

Brain Tumor Consortium for over 15 years and founded the Pacific Pediatric Neuro-Oncology Consortium 

(PNOC), a multi-institutional consortium of now 15 major academic centers across the United States. 

Currently Dr. Prados is Professor Emeritus at UCSF devoting his efforts towards pediatric Neuro-Oncology 

clinical and translational research. He is the co-Project Leader of a pediatric brain tumor SPORE project 

at UCSF and is co-Project Leader of the PNOC. His major interests are early phase clinical trials research 

and the translational studies that precede and inform those trials in both adults and children. He is part of 

the Editorial board of Neuro-Oncology, Journal of Neuro-Oncology and Journal of Clinical Oncology, and 

a member of the NCI/CTEP Brain Malignancies Steering Committee. In 2014 he was awarded the Victor 

Levin Award for lifetime clinical research excellence from the Society of Neuro-Oncology. 

http://cancer.ucsf.edu/people/profiles/prados_michael.3603 

__________________________________________________________________________ 

Encouraging survival with Toca 511 and Toca FC compared to external 

lomustine control. 

Authors*: Timothy Francis Cloughesy, Manish K. Aghi, Clark Chen, J. Bradley Elder, Santosh Kesari, 

Steven N. Kalkanis, George Kaptain, Joseph C. Landolfi, Tom Mikkelsen, Jana Portnow, Joan M. Robbins, 

Derek Ostertag, Asha Das, Alice Chu, Michael A. Vogelbaum 




Poster Session: Central Nervous System Tumors 



19

Presentations 

Precision Medicine in recurrent glioblastoma: A feasibility trial 

conducted by the Ivy Foundation Early Phase Clinical Trials Consortium. 

Authors*: Michael Prados, John G. Kuhn, Howard Colman, Timothy Francis Cloughesy, Susan Marina Chang, 

Nicholas A. Butowski, John Frederick De Groot, Patrick Y. Wen, Keith L. Ligon, Ingo K. Mellinghoff, 

Andrew S. Chi, Joanna J Phillips, Annette M Molinaro, Rebecca Halperin, Nhan Tran, Michael E. Berens, 

John D. Carpten, David W. Craig, Sara A. Byron 




Poster Session: Central Nervous System Tumors 


Prados Research Interests: Dr. Prados is a world-recognized Neuro-oncology expert. He led the Adult 

Brain Tumor Consortium for over 15 years and founded the Pacific Pediatric Neuro-Oncology Consortium 

(PNOC), a multi-institutional consortium of now 15 major academic centers across the United States. 

Currently Dr. Prados is Professor Emeritus at UCSF devoting his efforts towards pediatric Neuro-Oncology 

clinical and translational research. He is the co-Project Leader of a pediatric brain tumor SPORE project 

at UCSF and is co-Project Leader of the PNOC. His major interests are early phase clinical trials research 

and the translational studies that precede and inform those trials in both adults and children. He is part of 

the Editorial board of Neuro-Oncology, Journal of Neuro-Oncology and Journal of Clinical Oncology, and 

a member of the NCI/CTEP Brain Malignancies Steering Committee. In 2014 he was awarded the Victor 

Levin Award for lifetime clinical research excellence from the Society of Neuro-Oncology. 

http://cancer.ucsf.edu/people/profiles/prados_michael.3603 


20

Presentations 

Phase I/II study of VAL-083 in patients with recurrent glioblastoma. 

Authors*: Kent C. Shih, Manish R. Patel, Nicholas A. Butowski, Gerald Steven Falchook, Sani Haider Kizilbash, 

Jeffrey A. Bacha, Dennis Brown, Anne Steino, Richard Stephen Schwartz, Sarath Kanekal, Lorena Lopez, 

Howard A. Burris 






Butowski Research Interests: My research includes translational research and a wide range of clinical trials, 

including those with convection-enhanced delivery (CED) with real-time MRI imaging, targeted agents, 

immunotherapy, and combination strategies. I am the Director of Translational Research in Neuro-Oncology 

and lead the translational effort on behalf of the UCSF Brain Tumor Research Center and Preclinical Core. 

My work has helped to create the groundwork for allied research in neuro-oncology and an extensive 

UCSF clinical trial portfolio for patients with primary brain and spine tumors, including an assortment of 

immunotherapy trials and surgically based trials. I have also designed investigator initiated trials, including a 

clinical trial employing intratumoral delivery with real-time MRI imaging as well as those with a range of novel 

targets, molecular markers and imaging biomarkers. I have also authored a number of peer-reviewed papers 

and presented work at national and international meetings. 

https://www.ucsfhealth.org/nicholas.butowski 


21

Presentations 

Pilot study of T cells redirected to EGFRvIII with a chimeric antigen 

receptor in patients with EGFRvIII+ glioblastoma. 

Authors*: Donald M. O’Rourke, MacLean Nasrallah, Jennifer J. Morrissette, Jan J. Melenhorst, 

Simon F. Lacey, Keith Mansfield, Maria Martinez-Lage, Arati Suvas Desai, Steven Brem, Eileen Maloney, 

Suyash Mohan, Sumei Wang, Gaurav Verma, Jean-Marc Navenot, Angela Shen, Zhaohui Zheng, 

Bruce Levine, Hideho Okada, Carl H. June, Marcela Valderrama Maus 






Okada Research Interests: As a translational physician scientist, Dr. Okada and his lab are focused on 

development of novel immunotherapeutic strategies for brain tumor patients. For example, Dr. Okada 

conducted one of the first immune gene therapy trials in patients with malignant glioma. His lab was also the 

first to identify and fully characterized cytotoxic T-lymphocyte epitopes for gliomas. Dr. Okada has also 

delineated the role of an integrin receptor very late activation antigen-4 and chemokine CXCL10 in efficient 

trafficking of T-cells to brain tumor sites. Dr. Okada has integrated these findings to develop a number of 

vaccine trials in both adult and pediatric glioma patients. More recently, his group developed a novel chimeric 

antigen receptor targeting glioblastoma cells, and are currently conducting a pilot trial. 

http://neurosurgery.ucsf.edu/index.php/about_us_faculty_okada.html 


22

Presentations 

Clinical and genomic characterization of metastatic small cell/ 

neuroendocrine prostate cancer (SCNC) and intermediate atypical 

prostate cancer (IAC): Results from the SU2C/PCF/AARCWest Coast 

Prostate Cancer Dream Team (WCDT). 

Authors*: Eric Jay Small, Rahul Raj Aggarwal, Jiaoti Huang, Artem Sokolov, Li Zhang, Joshi J. Alumkal, 

Jack Youngren, Charles J. Ryan, Adam Foye, Robert Evan Reiter, Christopher P. Evans, Martin Gleave, 

Owen Witte, Josh Stuart, Theodore C. Goldstein, George V. Thomas, Lawrence D. True, Himisha Beltran, 

Mark A. Rubin, Tomasz M. Beer 




Poster Session: Genitourinary (Prostate) Cancer 


Small Research Interests: The Stand Up To Cancer Dream Team led by Dr. Eric Small is exploring the 

idea that resistance to hormonal therapy occurs as a result of the prostate cancer cells using common 

cellular responses - what the Dream Team calls “adaptive pathways” - to escape the current prostate 

cancer therapies. They believe that, by identifying these pathways and inhibiting them, they will be able to 

overcome treatment resistance and profoundly improve the care of men affected by this fatal disease. This 

team is a six institution consortium to include UC Los Angeles, UC Davis, UC Santa Cruz, University of 

British Columbia, Oregon Health and Sciences University, with UCSF as the lead administrative site. 

http://cancer.ucsf.edu/people/profiles/small_eric.3671 

__________________________________________________________________________ 

Characteristics and anticancer interventions (ACIs) in African American 

(AA) and Caucasian (CAU) patients (pts) treated with sipuleucel-T 

(sip-T): Real-world experience from the PROCEED registry. 

Authors*: Andrew J. Armstrong, Celestia S. Higano, Matthew R. Cooperberg, Chiledum Ahaghotu, 

Ronald F. Tutrone, Laurence H. Belkoff, Carl A. Olsson, Sanjay Goel, Robert Claude Tyler, Nancy N. Chang, 

Jennifer Susan LIll, A. Oliver Sartor 




Session: Genitourinary (Prostate) Cancer 



23

Presentations 

Persistence of AR signaling in small cell neuroendocrine prostate 

cancer (SCNC) and intermediate atypical carcinoma (IAC): Results from 

the SU2C/PCF/AACR West Coast Prostate Cancer Dream Team (WCDT). 

Authors*: Rahul Raj Aggarwal, Jack Youngren, Artem Sokolov, Jiaoti Huang, George V. Thomas, 

Lawrence D. True, Adam Foye, Joshi J. Alumkal, Charles J. Ryan, Tomasz M. Beer, Christopher P. Evans, 

Martin Gleave, Matthew Rettig, Joshua M. Stuart, Primo Lara, Theodore C. Goldstein, Li Zhang, 

Robert Evan Reiter, Kim N. Chi, Eric Jay Small 















24

Presentations 

IMAAGEN trial safety and efficacy update: Effect of abiraterone 

acetate and low-dose prednisone on prostate-specific antigen and 

radiographic disease progression in patients with nonmetastatic 

castration-resistant prostate cancer. 

Authors*: Charles J. Ryan, E. David Crawford, Neal D. Shore, Willie Underwood, Mary-Ellen Taplin, 

Anil Londhe, Peter St. John Francis, Jennifer Phillips, Tracy McGowan, Philip W. Kantoff 






Ryan Research Interests: Dr. Ryan’s clinical practice focuses predominantly on advanced prostate cancer 

as well as germ cell (testicular) tumors and other malignancies of the genitourinary tract. His clinical 

and research work centers on the design and conduct of clinical trials of novel therapies for advanced 

prostate cancer, specifically secondary hormonal therapies targeting adrenal androgen signaling, androgen 

receptor targeted therapy and chemotherapy. In addition to clinical trials, Dr. Ryan collaborates with many 

laboratories researching the role of the androgen receptor and other signaling mechanisms in prostate 

cancer patients. 

http://cancer.ucsf.edu/people/profiles/ryan_charles.3649 


25

Presentations 

Updated results: A phase I/IIa randomized trial of radium-223 + 

docetaxel versus docetaxel in patients with castration-resistant 

prostate cancer and bone metastases. 

Authors*: Michael J. Morris, Yohann Loriot, Christopher Sweeney, Karim Fizazi, Charles J. Ryan, 

Daniel H. Shevrin, Emmanuel S. Antonarakis, John Reeves, Kumari Chandrawansa, Martin Kornacker, 

Celestia S. Higano 















26

Presentations 

Immunogenicity of sipuleucel-T (Sip-T) in abiraterone (Abi)/ 

enzalutamide (Enz) sensitive and resistant metastatic castrateresistant 

prostate cancer (mCRPC). 

Authors*: Eric Jay Small, Lawrence Fong, David I. Quinn, Charles G. Drake, Dwayne Campogan, Tuyen Vu, 

Nadeem Anwar Sheikh, Nancy N. Chang, Daniel Peter Petrylak 














__________________________________________________________________________ 

Preliminary results for the advanced salivary gland carcinoma cohort 

of the phase 1b KEYNOTE-028 study of pembrolizumab. 

Authors*: Roger B. Cohen, Jean-Pierre Delord, Toshihiko Doi, Sarina Anne Piha-Paul, Stephen V. Liu, Jill Gilbert, 

Alain Patrick Algazi, Sara Cresta, Ruey-Long Hong, Christophe Le Tourneau, Daphne Day, Andrea Varga, 

Elena Elez, John M. Wallmark, Sanatan Saraf, Anne Morosky, Jonathan D. Cheng, Bhumsuk Keam 




Session: Head and Neck Cancer 



27

Presentations 

Predicting overall survival (OS) and progression-free (PFS) for oropharynx 

cancers (OPC) in NRG Oncology RTOG0129/0522 with nomograms. 

Authors*: Carole Fakhry, Qiang Zhang, Maura L. Gillison, Phuc Duy Nguyen, David Ira Rosenthal, 

Randal S. Weber, Louise Lambert, Andy Trotti, William Barrett, Wade Thorstad, Sue S Yom, Stuart J. Wong, 

John A. Ridge, Shyam S. Rao, James A. Bonner, Eric Vigneault, David Raben, Jonathan Harris, Quynh-Thu Le 






Yom Research Interests: Dr. Yom is an expert in head and neck, thoracic, and skin cancers and conducts 

research in quality of life and supportive care, patient-oriented decision making, and combinations of novel 

targeted therapies and immunotherapy with radiation therapy. She is the principal investigator of HN002, 

a national trial in de-intensified therapy for HPV+ oropharyngeal cancer. She serves on several national 

panels developing guidelines for appropriate care of head and neck cancers. 

http://profiles.ucsf.edu/sue.yom 

__________________________________________________________________________ 

The prognostic role of gender, race and human papillomavirus (HPV) 

in oropharyngeal squamous cell cancer (OPC) and non-oropharyngeal 

head and neck squamous cell cancer (non-OP HNC). 

Authors*: Carole Fakhry, William H. Westra, Steven Wang, Annemieke VanZante, Yuehan Zhang, 

Eleni Marie Rettig, Alicia Wentz, Young Jun Kim, Justin A. Bishop, Wayne Koch, Christine Gail Gourin, 

Jeremy Richmon, David Eisele, Gypsyamber D’Souza 







28

Presentations 

Pembrolizumab for advanced papillary or follicular thyroid cancer: 

preliminary results from the phase 1b KEYNOTE-028 study. 

Authors*: Janice M. Mehnert, Andrea Varga, Marcia Brose, Rahul Raj Aggarwal, Chia-Chi Lin, Amy Prawira, 

Filippo de Braud, Kenji Tamura, Toshihiko Doi, Sarina Anne Piha-Paul, Jill Gilbert, Sanatan Saraf, 

Pradeep Thanigaimani, Jonathan D. Cheng, Bhumsuk Keam 






__________________________________________________________________________ 

Impact of industry funding and collaboration in oncology RCTs. 

Authors*: Anne Linker, Nitin Roper, Annie Yang, Deborah Korenstein 




Poster Session: Health Services Research and Quality of Care 



29

Presentations 

KEYNOTE-006 study of pembrolizumab (pembro) versus ipilimumab 

(ipi) for advanced melanoma: Efficacy by PD-L1 expression and line 

of therapy. 

Authors*: Adil Daud, Christian U. Blank, Caroline Robert, Igor Puzanov, Erika Richtig, Kim Allyson Margolin, 

Steven O’Day, Marta Nyakas, Jose Lutzky, Ahmad A. Tarhini, Elaine McWhirter, Christian Caglevic, 

Peter Mohr, Michael Millward, Marcus O. Butler, Honghong Zhou, Kenneth Emancipator, Scot Ebbinghaus, 

Nageatte Ibrahim, Georgina V. Long 




Poster Session: Melanoma/Skin Cancers 


Daud Research Interests: Our group at UCSF is focused on developing new immunotherapy agents and 

specifically understanding the biology of the immune response to PD-1 in melanoma. We developed IL- 

12 gene therapy in melanoma and carried out the first in human clinical trial in 2005-2007. Based on this 

work, IL-12 electroporation is being explored in many cancers as an immune agent and as a combination 

treatment with PD-1 and other checkpoint inhibitors in melanoma. I have been involved in the development 

of anti-PD-1 antibodies for melanoma. With my colleagues Michael Rosenblum and Max Krummel at 

UCSF, we have developed a novel assay that profiles the intra-tumoral microenvironment in depth and can 

predict non-response to PD-1. We are currently exploring novel strategies for PD-1 non-responsive subsets 

of melanoma (and potentially other cancers). 

http://cancer.ucsf.edu/people/profiles/daud_adil.3622 

__________________________________________________________________________ 

Anti-PD-1 therapy in patients with advanced melanoma and preexisting 

autoimmune disorders (AD) or major toxicity with ipilimumab (IPI). 

Authors*: Alexander M. Menzies, Douglas Buckner Johnson, Sangeetha Ramanujam, Victoria Atkinson, 

Annie N.M. Wong, John J Park, Jennifer Leigh McQuade, Alexander Noor Shoushtari, Katy K. Tsai, 

Zeynep Eroglu, Oliver Klein, Jessica Cecile Hassel, Jeffrey Alan Sosman, Alex Guminski, Ryan J. Sullivan, 

Antoni Ribas, Matteo S. Carlino, Michael A. Davies, Shahneen Kaur Sandhu, Georgina V. Long 




Session: Melanoma/Skin Cancers 



30

Presentations 

Novel T cell exhaustion marker to predict monotherapy PD-1 compared 

to combination CTLA-4 and PD-1 response in melanoma. 

Authors*: Kimberly Loo, Katy K. Tsai, Mariela Pauli, Priscila Munoz Sandoval, Michael Alvarado, 

Alain Patrick Algazi, Michael Rosenblum, Adil Daud 

















31

Presentations 

Preliminary results from phase II study of combination treatment with 

HF10, a replication-competent HSV-1 oncolytic virus, and ipilimumab in 

patients with stage IIIb, IIIc, or IV unresectable or metastatic melanoma. 

Authors*: Robert Hans Ingemar Andtbacka, Merrick I. Ross, Sanjiv S. Agarwala, Matthew H. Taylor, 

John T. Vetto, Rogerio Izar Neves, Adil Daud, Hung T. Khong, Richard S. Ungerleider, Aislyn Boran, 

Maki Tanaka, Kenneth F. Grossmann 

















32

Presentations 

Correlation between metastatic site and response to anti- 

Programmed Death-1 (PD-1) agents in melanoma. 

Authors*: Simone M. Goldinger, Katy K. Tsai, Paul Tumeh, Omid Hamid, Adi Nosrati, Kimberly Loo, 

Barbara Grimes, Alain Patrick Algazi, Mitchell P. Levesque, Reinhard Dummer, Adil Daud 

















33

Presentations 

A randomized, phase 3, open-label study of nivolumab versus 

temozolomide (TMZ) in combination with radiotherapy (RT) in 

adult patients (pts) with newly diagnosed, O-6-methylguanine DNA 

methyltransferase (MGMT)-unmethylated glioblastoma (GBM): 

CheckMate-498. 

Authors*: John H. Sampson, Antonio Marcilio Padula Omuro, Matthias Preusser, Michael Lim, 

Nicholas A. Butowski, Timothy Francis Cloughesy, Lewis C. Strauss, Robert Raymond Latek, Prashni 

Paliwal, Michael Weller, David A. Reardon 



Location: Hall A, Poster Board #265b 














__________________________________________________________________________ 

Phase 2 study to evaluate the clinical efficacy and safety of 

MEDI4736 (durvalumab) in patients with glioblastoma (GBM). 

Authors*: David A. Reardon, Thomas Joseph Kaley, Jorg Dietrich, Michael Lim, Gavin P Dunn, 

Hui Kong Gan, Timothy Francis Cloughesy, Jennifer Leigh Clarke, Andrew J. Park, Mary J. Macri, 

Aileen Ryan, Toni Ricciardi, Vijay Reddy, Ralph Rudolph Venhaus 







34

Presentations 

ATLAS: A randomized, double-blind, placebo-controlled, phase 3 

trial of apalutamide (ARN-509) in patients with high-risk localized or 

locally advanced prostate cancer receiving primary radiation therapy. 

Authors*: Howard M. Sandler, Michael R. McKenzie, Bertrand F. Tombal, Edwina Baskin-Bey, 

Stephen J. Freedland, Mack Roach, Anders Widmark, Alberto Bossi, Adam Dicker, Thomas Wiegel, 

Neal D. Shore, Matthew Raymond Smith, Margaret K. Yu, Thian Kheoh, Shibu Thomas, David P. Dearnaley 






__________________________________________________________________________ 

Intense exercise for survival among men with metastatic castrateresistant 

prostate cancer (INTERVAL – MCRPC): A Movember funded 

multicenter, randomized, controlled phase III study. 

Authors*: Fred Saad, Stacey A. Kenfield, June M. Chan, Nicolas H. Hart, Kerry S. Courneya, James Catto, 

Stephen P. Finn, Rosemary Greenwood, Daniel C Hughes, Lorelei A. Mucci, Stephen R Plymate, 

Michael N. Pollak, Stephan F.E. Praet, Aaron P. Russell, Emer M. Guinan, Erin Van Blarigan, Orla Casey, 

Mark Buzza, Charles J. Ryan, Robert Usher Newton 















35

Presentations 

Clinical activity of anti-programmed death-1 (PD-1) agents in acral and 

mucosal melanoma. 

Authors*: Rodrigo Ramella Munhoz, Alexander Noor Shoushtari, Deborah Kuk, Patrick Alexander Ott, 

Douglas Buckner Johnson, Katy K. Tsai, Suthee Rapisuwon, Zeynep Eroglu, Ryan J. Sullivan, 

Jason John Luke, Tara C. Gangadhar, April K. Salama, Varina Clark, Clare Burias, Igor Puzanov, 

Michael B. Atkins, Alain Patrick Algazi, Antoni Ribas, Jedd D. Wolchok, Michael Andrew Postow 






__________________________________________________________________________ 

Randomized phase II/III trial of active immunotherapy with OPT-822/ 

OPT-821 in patients with metastatic breast cancer. 

Authors*: Chiun-Sheng Huang, Alice L Yu, Ling-Ming Tseng, Louis W. C. Chow, Ming-Feng Hou, 

Sara A. Hurvitz, Richard B. Schwab, Chi-Huey Wong, James L. Murray, Hsien-Kun Chang, Hong-Tai Chang, 

Shin-Cheh Chen, Sung-Bae Kim, Youe-Kong Shue, Hope S. Rugo 




Session: Breast Cancer - Triple-Negative/Cytotoxics/Local Therapy 














36

Presentations 

A prospective analysis of surgery and survival in stage IV breast 

cancer (TBCRC 013). 

Authors*: Tari A. King, Jaclyn Lyman, Mithat Gonen, Sylvia Reyes, Eun-Sil Shelley Hwang, Hope S. Rugo, 

Minetta C. Liu, Judy Caroline Boughey, Lisa K. Jacobs, Kandace P. McGuire, Anna Maria Storniolo, 

Claudine Isaacs, Ingrid M. Meszoely, Catherine H. Van Poznak, Gildy Babiera, Larry Norton, Monica Morrow, 

Antonio C. Wolff, Eric P. Winer, Clifford A. Hudis, Translational Breast Cancer Research Consortium (TBCRC) 


















37

Presentations 

Genes Versus T-Cells 

Authors*: Chloe Evelyn Atreya 

Abstract #: 

Presentation Date/Time: Saturday, June 4: 1:51-2:03 PM 


Poster Discussion Session: Gastrointestinal (Colorectal) Cancer 

Citation: 

Atreya Research Interests: Dr. Atreya specializes in gastrointestinal cancer, particularly colorectal cancer. Her 

research focuses on the interplay of tumor genetics and response to therapies for colorectal cancer, with the 

goal of improving patient outcomes and quality of life by personalizing treatment. Dr. Atreya is the recipient 

of numerous awards, including the Conquer Cancer Foundation of the American Society of Clinical Oncology 

Young Investigator Award and Alliance for Clinical Trials in Oncology Foundation Investigator Award. She 

is the recipient of a National Cancer Institute/National Institutes of Health K08 Career Development Award 

for Targeting of Aberrant Signaling in Patient-Derived Colorectal Cancer Models. Dr. Atreya is a member of 

the American Society of Clinical Oncologists, American Association of Cancer Researchers and Alliance for 

Clinical Trials in Oncology, Gastrointestinal Committee. 

http://cancer.ucsf.edu/gi/chloe-atreya 

__________________________________________________________________________ 

Developing a Road Map to Guide Immunotherapy 

Authors*: Lawrence Fong 

Abstract #: 


Location: Hall B1 

Oral Abstract Session: Developmental Therapeutics - Immunotherapy 

Citation: 

Fong Research Interests: My lab focuses on how the immune system interacts with cancer as well as exploring 

tumor immunotherapies in mouse models and in patients. Our primary focus is in cancer immunotherapy. 

We investigate how immunotherapies such as immune checkpoint inhibitors and cancer vaccines can 

enhance anti-tumor immunity both systemically and in the tumor microenvironment. Performing neoadjuvant 

immunotherapy trials, we determine how specific therapies can recruit immune effectors in cancer patients. 

Moreover, we have studied how clinical responders may differ from clinical non-responders. We are applying 

unbiased approaches to studying antigen-specific responses that are modulated in these patients and are 

currently developing biomarkers that may be redictive of clinical efficacy. 

http://hemonc.ucsf.edu/fonglab/ 


38

Presentations 

Circulating Biomarkers: Where Are We Now? 

Authors*: Terrence W. Friedlander 

Abstract #: 

Presentation Date/Time: Saturday, June 4: 4:45 - 4:57 Pm 


Poster Discussion Session: Genitourinary (Prostate) Cancer 

Citation: 

Friedlander Research Interests: I am a clinical and translational oncologist specializing in cancers of the 

genitourinary tract, specifically bladder and prostate cancers. My research is focused on understanding 

the basic biology of these malignancies and in developing novel therapeutic ways to treat disease. In 

recent years my works has explored the prognostic and predictive value of circulating tumor cells (CTCs) 

in these malignancies. In addition to work exploring CTCs as biomarkers of response and resistance, I have 

investigated the structural and epigenetic state of advanced prostate cancer, and this work has led to a number 

of grants and publications. Additionally I have a research focus in immunology, particularly in bladder cancer. 

As a clinical academic oncologist I serve as principal investigator or co-investigator on a number of clinical trials 

in advanced prostate and bladder cancer, which allows us to recruit patients for much of our biomarker work. 

http://cancer.ucsf.edu/people/profiles/friedlander_terence.4963 

__________________________________________________________________________ 

Early Phase Clinical Trials 

Authors*: Nicholas A. Butowski 

Abstract #: 



Poster Discussion Session: Central Nervous System Tumors 

Citation: 













39

Presentations 

Clinical and genomic characterization of metastatic small cell/ 

neuroendocrine prostate cancer (SCNC) and intermediate atypical 

prostate cancer (IAC): Results from the SU2C/PCF/AARCWest Coast 

Prostate Cancer Dream Team (WCDT). 

Authors*: Eric Jay Small, Rahul Raj Aggarwal, Jiaoti Huang, Artem Sokolov, Li Zhang, Joshi J. Alumkal, 

Jack Youngren, Charles J. Ryan, Adam Foye, Robert Evan Reiter, Christopher P. Evans, Martin Gleave, 

Owen Witte, Josh Stuart, Theodore C. Goldstein, George V. Thomas, Lawrence D. True, Himisha Beltran, 

Mark A. Rubin, Tomasz M. Beer 




Poster Discussion Session: Genitourinary (Prostate) Cancer 











40

Presentations 

Extended follow-up results of a phase 1B study (BRIM7) of 

cobimetinib (C ) and vemurafenib (V) in BRAF-mutant melanoma. 

Authors*: Adil Daud, Anna C. Pavlick, Antoni Ribas, Rene Gonzalez, Karl D. Lewis, Omid Hamid, 

Thomas Gajewski, Igor Puzanov, Jessie J. Hsu, Daniel O. Koralek, Nicholas W. Choong, Grant A. McArthur 




Poster Discussion Session: Melanoma/Skin Cancers 













41

Presentations 

Derivation and validation of a prediction scale for response to 

PD-1 monotherapy. 

Authors*: Adi Nosrati, Simone M. Goldinger, Katy K. Tsai, Kimberly Loo, Paul Tumeh, Omid Hamid, 

Alain Patrick Algazi, Mitchell P. Levesque, Reinhard Dummer, Adil Daud 




Poster Discussion Session: Melanoma/Skin Cancers 













42

Presentations 

Adjuvant temozolomide for low grade gliomas: Molecular and 

radiographic correlates of treatment response in a phase II clinical trial. 

Authors*: Michael Traut Wahl, Joanna J Phillips, Annette M Molinaro, Yi Lin, Arie Perry, 

Daphne Haas-Kogan, Joseph F Costello, Manisha Dayal, Nicholas A. Butowski, Jennifer Leigh Clarke, 

Michael Prados, Mitchel S. Berger, Sarah J. Nelson, Susan Marina Chang 


Presentation Date/Time: Sunday, June 5: 8:00 - 11:00 AM 

Location: S100a 

Oral Abstract Session: Central Nervous System Tumors 


Chang Research Interests: My research interest is in the development of novel therapies for patients with 

brain tumors, as well as the assessment of novel imaging biomarkers in the management of patients. 

My research seeks to integrate advances in physiologic and metabolic imaging with tissue biomarkers in 

order to optimize the management of patients with glioblastoma (GBM). My clinical research evaluates a 

wide spectrum of therapeutic interventions that span chemotherapy, targeted agents, immunotherapy and 

convection enhanced delivery of novel agents. I am the site PI of an NIH-funded adult brain tumor 

consortium and am a member of the Brain Malignancy Steering Committee and the Developmental 

Therapeutics Study Section at the NIH. I am the program leader for the Neuro-Oncology Program at the 

HDFCCC. I am the clinical co-PI for the UCSF Brain Tumor SPORE and a co-Leader of a SPORE Project 

evaluating the role of physiologic imaging in the determination of malignant progression of low-grade glioma. 



43

Presentations 

Impact of primary (1º) tumor location on overall survival (OS) and 

progression-free survival (PFS) in patients (pts) with metastatic 

colorectal cancer (mCRC): Analysis of CALGB/SWOG 80405 (Alliance). 

Authors*: Alan P. Venook, Donna Niedzwiecki, Federico Innocenti, Briant Fruth, Claire Greene, Bert H. 

O’Neil, James Edward Shaw, James Norman Atkins, Laura E. Horvath, Blase N. Polite, Jeffrey A. Meyerhardt, 

Eileen Mary O’Reilly, Richard M. Goldberg, Howard S. Hochster, Charles David Blanke, Richard L. Schilsky, 

Robert J. Mayer, Monica M. Bertagnolli, Heinz-Josef Lenz 













__________________________________________________________________________ 

The relationship between primary tumor sidedness and prognosis in 

colorectal cancer. 

Authors*: Deborah Schrag, Shicheng Weng, Gabriel Brooks, Jeffrey A. Meyerhardt, Alan P. Venook 














44

Presentations 

Ribociclib (LEE011) and letrozole in estrogen receptor-positive (ER+), 

HER2-negative (HER2–) advanced breast cancer (aBC): Phase Ib 

safety, preliminary efficacy and molecular analysis. 

Authors*: Dejan Juric, Pamela N. Munster, Mario Campone, Roohi Ismail-Khan, Laura García-Estevez, 

Erika Paige Hamilton, Carlos Becerra, Richard H. De Boer, Rina Hui, Anthony Goncalves, Yingbo Wang, 

Shyeilla V. Dhuria, Ghulam H. Kalimi, Karen Cristina Rodriguez Lorenc, Ingrid A. Mayer 




Session: Breast Cancer - HER2/ER 


Munster Research Interests: My clinical research interests are first-in-human early phase clinical trials of 

novel compounds and alternative strategies for the treatment and prevention of cancer. I have been involved 

in clinical and translational research in early phase clinical trials since 1998. As the program leader for 

Development Therapeutics and the PI of a peer-reviewed basic science lab, my main focus is on translating 

preclinical findings into early-stage clinical trials with extensive PK and integration of PD correlative studies 

and molecular imaging for patients with advanced stage cancer. My basic research interest is centered on 

the role of epigenetic modification in therapy resistance in breast cancer and epigenetic priming. In addition 

to studying basic mechanisms of hormone therapy resistance, we have shown that epigenetic modification 

plays a crucial role in the hormonal regulation and carcinogenesis of breast cancer. 

http://cancer.ucsf.edu/people/profiles/munster_pamela.3449 

__________________________________________________________________________ 

Outcome disparities by age and 21-gene recurrence score (RS) in 

hormone receptor positive (HR+) breast cancer (BC). 

Authors*: Valentina I. Petkov, Dave P. Miller, Nadia Howlader, Nathan Gliner, Will Howe, Nicola C. Schussler, 

Kathleen Cronin, Frederick L. Baehner, Lynne Penberthy, Steven Shak 




Session: Breast Cancer- HER2/ER 



45

Presentations 

Phase 1 study of CB-839, a small molecule inhibitor of glutaminase 

(GLS) in combination with paclitaxel (Pac) in patients (pts) with triple 

negative breast cancer (TNBC). 

Authors*: Angela DeMichele, James J. Harding, Melinda L. Telli, Pamela N. Munster, Rana McKay, 

Othon Iliopoulos, Keith W. Orford, Mark K. Bennett, James Walter Mier, Taofeek Kunle Owonikoko, 

Manish R. Patel, Richard D. Carvajal, Funda Meric-Bernstam, Jeffrey R. Infante 

















46

Presentations 

Androgen receptor (AR) expression in primary breast cancer (BC): 

Correlations with clinical characteristics and outcomes. 

Authors*: Neelima Vidula, Christina Yau, Denise M Wolf, Hope S. Rugo 




Poster Session: Breast Cancer - Triple-Negative/Cytotoxics/Local Therapy 














47

Presentations 

Efficacy of a novel antibody-drug conjugate (ADC), ABT-414, as 

monotherapy in epidermal growth factor receptor (EGFR) amplified, 

recurrent glioblastoma (GBM). 

Authors*: Martin J. Van Den Bent, Hui Kong Gan, Andrew B. Lassman, Priya Kumthekar, Ryan Merrell, 

Nicholas A. Butowski, Zarnie Lwin, Tom Mikkelsen, Louis B. Nabors, Kyriakos P. Papadopoulos, 

Marta Penas-Prado, John Simes, Helen Wheeler, Erica J. Gomez, Ho-Jin Lee, Lisa Roberts-Rapp, 

Hao Xiong, Earle E. Bain, Kyle D. Holen, David A. Reardon 




Session: Developmental Therapeutics - Clinical Pharmacology and Experimental Therapeutics 














48

Presentations 

Efficacy and hematologic toxicity of carboplatin and talazoparib 

combination therapy in BRCA mutated patients. 

Authors*: Mallika Sachdev Dhawan, Rahul Raj Aggarwal, Imke Bartelink, Jim Leng, Scott Thomas, 

Nela Pawlowska, Laurie Stevenson, Amy Jo Chien, Robin Kate Kelley, Julia Clennell, Pamela N. Munster 




Poster Session: Developmental Therapeutics - Clinical Pharmacology and Experimental Therapeutics 













49

Presentations 

Association between T cell repertoire diversification and both clinical 

response as well as toxicity following immune checkpoint blockade in 

metastatic cancer patients. 

Authors*: David Yoonsuk Oh, Jason Cham, Li Zhang, Grant Fong, Mark Klinger, Malek Faham, 

Lawrence Fong 




Post Session: Developmental Therapeutics - Immunotherapy 












50

Presentations 

IMpassion130: a Phase III randomized trial of atezolizumab with nabpaclitaxel 

for first-line treatment of patients with metastatic triplenegative 

breast cancer (mTNBC). 

Authors*: Leisha A. Emens, Sylvia Adams, Sherene Loi, Andreas Schneeweiss, Hope S. Rugo, Eric P. Winer, 

Carlos H. Barrios, Veronique Dieras, Juan de la Haba-Rodriguez, Luca Gianni, Stephen Y. Chui, Peter Schmid 


















51

Presentations 

A randomized, double-blind, placebo-controlled study of ibrutinib, a 

Bruton tyrosine kinase inhibitor, with nab-paclitaxel and gemcitabine 

in the first-line treatment of patients with metastatic pancreatic 

adenocarcinoma (RESOLVE). 

Authors*: Margaret A. Tempero, Lisa M Coussens, Lawrence Fong, Robert Manges, Priyanka Singh, 

Yunfeng Li, George W. Cole, Danelle Frances James, Josep Tabernero 




Poster Session: Developmental Therapeutics - Clinical Pharmacology and Experimental Therapeutics 


Tempero Research Interests: My research focuses on pancreatic ductal adenocarcinoma, especially in 

investigational therapeutics. I was a pioneer in the use of mAb-based therapies and helped develop the fixed 

dose rate concept for gemcitabine. My group developed effective gemcitabine combinations, provided a 

foundation for using CA19-9 as a clinical surrogate for survival and currently is assessing molecular subtypes 

and molecular enrichment for selecting new drugs for clinical evaluation. We have a strong emphasis on 

immunotherapy. I am a SU2C Dream Team member evaluating innovative immunotherapy approaches in this 

disease. I am also co-PI of a U01 award to establish high risk cohorts for testing candidate early diagnosis 

biomarkers. I am the UCSF Pancreas Center Director and Pancreas Cancer Program Leader. I have served 

as the NCCN Guidelines Panel Chair on Pancreatic Cancer since 2000. I serve on SABs to many groups and 

institutions including the Mayo Clinic Pancreas Cancer SPORE and MDACC’s Moon Shot Program. 

http://cancer.ucsf.edu/people/profiles/tempero_margaret.3701 


52

Presentations 

Randomized phase II trial of a DNA vaccine encoding prostatic 

acid phosphatase (PAP) versus GM-CSF adjuvant in patients with 

biochemically recurrent prostate cancer. 

Authors*: Glenn Liu, Lawrence Fong, Emmanuel S. Antonarakis, Jens C. Eickhoff, Laura E. Johnson, 

Douglas G. McNeel 




Session: Developmental Therapeutics - Immunotherapy 












53

Presentations 

SOLAR-1: A phase III study of alpelisib + fulvestrant in men and 

postmenopausal women with HR+/HER2– advanced breast cancer 

(BC) progressing on or after prior aromatase inhibitor therapy. 

Authors*: Fabrice Andre, Mario Campone, Eva M. Ciruelos, Hiroji Iwata, Sibylle Loibl, Hope S. Rugo, 

Celine Wilke, David Mills, Marie Chol, Anne-Sophie Longin, Dejan Juric 


















54

Presentations 

Phase II trial with tamoxifen in combination with vorinostat and 

pembrolizumab in estrogen receptor (+) hormone therapy resistant 

metastatic breast cancer patients (NCT02395627). 

Authors*: Manuela Terranova Barberio, Scott Thomas, Amy Jo Chien, Hope S. Rugo, Michelle E. Melisko, 

Austin Nicholas Angelidakis, Nela Pawlowska, Travis Deal, Pamela N. Munster 




Poster Session: Breast Cancer - HER2/ER 













55

Presentations 

A phase 2 randomized, double-blind, placebo-controlled trial of 

endocrine therapy ± radium-223 dichloride (Ra-223) in HER2- hormone 

receptor+breast cancer patients with bone metastases. 

Authors*: Robert E. Coleman, Rui Li, Amrita G. Sawhney, Oana Petrenciuc, Hope S. Rugo 


















56

Presentations 

Academic and Community Cancer Research United (ACCRU) 

RU011301I: Adjuvant ado-trastuzumab emtansine (T-DM1) for older 

patients with human epidermal growth factor receptor 2 (HER2)- 

positive breast cancer. 

Authors*: Rachel A. Freedman, Mei-Yin Polley, Amylou C. Dueck, Arti Hurria, Hyman B. Muss, 

Kathryn Jean Ruddy, Joleen Marie Hubbard, Heshan Liu, Lauren J. Rogak, Ethan M. Basch, 

Shaker R. Dakhil, Jason D. Huff, Madhuri Bajaj, Mary Wilkinson, Tareq Al Baghadadi, Sam Benjamin, 

Rex B Mowat, Clifford A. Hudis, Hope S. Rugo, Eric P. Winer 


















57

Presentations 

SOPHIA: A phase 3, randomized study of margetuximab (M) plus 

chemotherapy (CTX) vs trastuzumab (T) plus CTX in the treatment of 

patients with HER2+ metastatic breast cancer (MBC). 

Authors*: Hope S. Rugo, Mark D. Pegram, William John Gradishar, Javier Cortes, Giuseppe Curigliano, 

Jon M. Wigginton, Robert Joseph Lechleider, Fatima Cardoso 









patients, including with UCSFs Advanced Breast Cancer Program. Dr. Rugo has numerous collaborations with 









58

Presentations 

Prevention of everolimus/exemestane (EVE/EXE) stomatitis in 

postmenopausal (PM) women with hormone receptor-positive (HR+) 

metastatic breast cancer (MBC) using a dexamethasone-based 

mouthwash (MW): Results of the SWISH trial. 

Authors*: Hope S. Rugo, Lasikas Seneviratne, J. Thaddeus Beck, John A. Glaspy, Julio Antonio Peguero, 

Timothy J. Pluard, Navneet Dhillon, Leon C. Hwang, Chaitali Singh Nangia, Ingrid A. Mayer, Timothy F. Meiller, 

Mark Steven Chambers, Ghulam Warsi, Robert William Sweetman, J. Randy Sabo, Jennifer Keating Litton 


















59

Presentations 

Addition of pazopanib (PZ) to endocrine therapy in hormone resistant 

advanced breast cancer (ABC.) 

Authors*: Melanie Catherine Majure, Ariadna Gasol Cudós, Austin Nicholas Angelidakis, 

Michelle E. Melisko, Ariel R. Karwat, Amy Jo Chien, Andrei Goga, Mark M. Moasser, John W. Park, 

Amy N. DeLuca, Hope S. Rugo 




Poster Session: Breast Cancer- HER2/ER 




stage breast cancer (BC). She also works on studies to improve supportive care for early & late stage 

BC patients, including with UCSFs Advanced Breast Cancer Program. Dr. Rugo has numerous collaborations 

with large academic medical centers & consortia in order to expand the novel therapies available to patients. 

She was the director of the 2016 ASCO Breast Cancer Education Committee meeting, is a member of the 

Alliance & is a founding member of the Breast Cancer Research Consortium where she co-leads the triple 

negative working group. She is on the novel agents committee for the neoadjuvant multi-center I SPY2 trial. 

At UCSF, Dr. Rugo runs the Breast Forum, a bimonthly educational session for breast cancer patients, families 

& friends from throughout the bay area. 



60

Presentations 

A phase 2 randomized, double-blind, placebo-controlled trial of 

radium-223 dichloride with exemestane and everolimus in patients 

with HER2-negative hormone receptor-positive breast cancer and 

bone metastases. 

Authors*: Hope S. Rugo, Rui Li, Oana Petrenciuc, Amily Zhang, Robert E. Coleman 


















61

Presentations 

Impact of primary (1˚) tumor location on overall survival (OS) and 

progression-free survival (PFS) in patients (pts) with metastatic 

colorectal cancer (mCRC): Analysis of CALGB/SWOG 80405 (Alliance). 

Authors*: Alan P. Venook, Donna Niedzwiecki, Federico Innocenti, Briant Fruth,Claire Greene, Bert H. O’Neil, 

James Edward Shaw, James Norman Atkins, Laura E. Horvath, Blase N. Polite, Jeffrey A. Meyerhardt, 

Eileen Mary O’Reilly, Richard M. Goldberg, Howard S. Hochster, Charles David Blanke, Richard L. Schilsky, 

Robert J. Mayer, Monica M. Bertagnolli, Heinz-Josef Lenz 


Presentation Date/Time: Sunday, June 5: 8:00 – 11:00AM 


Oral Abstract Session: Gastrointestinal (Colorectal) Cancer 










62

Presentations 

PD-L1 expression, Cancer Genome Atlas (TCGA) subtype, and 

mutational load as independent predictors of response to 

atezolizumab (atezo) in metastatic urothelial carcinoma (mUC; 

IMvigor210). 

Authors*: Jonathan E. Rosenberg, Daniel Peter Petrylak, Michiel Simon Van Der Heijden, Andrea Necchi, 

Peter H. O’Donnell, Yohann Loriot, Margitta Retz, Jose Luis Perez-Gracia, Joaquim Bellmunt, Petros Grivas, 

Richard Wayne Joseph, Lawrence Fong, Edward E. Kadel, Zachary Boyd, Dorothee Nickles, 

Garrett Michael Frampton, Richard Bourgon, Priti S. Hegde, Sanjeev Mariathasan, Thomas Powles 




Session: Immunotherapy: Now We’re Getting Personal - Using Genomics and Biomarkers to Predict Response 












63

Presentations 

Pembrolizumab in patients with advanced cervical squamous cell 

cancer: Preliminary results from the phase Ib KEYNOTE-028 study. 

Authors*: Jean-Sebastien Frenel, Christophe Le Tourneau, Bert H. O’Neil, Patrick Alexander Ott, 

Sarina Anne Piha-Paul, Carlos Alberto Gomez-Roca, Emilie Van Brummelen, Hope S. Rugo, Shari Thomas, 

Sanatan Saraf, Mei Chen, Andrea Varga 


Presentation Date/Time: Sunday, June 5: 9:45 AM - 12:45 PM 

Location: E450ab 

Session: Gynecologic Cancer 














64

Presentations 

The Heart of the Matter 

Authors*: Pamela N. Munster 

Abstract #: 

Presentation Date/Time: Sunday, June 5: 5:21 - 5:33 PM 


Poster Discussion Session: Breast Cancer - Triple-Negative/Cytotoxics/Local Therapy 

Citation: 












65

Presentations 

Phase III randomized study of sorafenib plus doxorubicin versus 

sorafenib in patients with advanced hepatocellular carcinoma (HCC): 

CALGB 80802 (Alliance). 

Authors*: Ghassan K. Abou-Alfa, Donna Niedzwieski, Jennifer J. Knox, Andreas Kaubisch, James Posey, 

Benjamin R. Tan, Petr Kavan, Rakesh Goel, Philip Edward Lammers, Tanios S. Bekaii-Saab, 

Vincent Channing Tam, Lakshmi Rajdev, Robin Kate Kelley, Abby B. Siegel, Jennifer Balletti, 

James J. Harding, Lawrence Howard Schwartz, Richard M. Goldberg, Monica M. Bertagnolli, Alan P. Venook 


Presentation Date/Time: Monday, June 6: 8:00 - 11:00 AM 












66

Presentations 

4-year results of the ponatinib phase II PACE trial in patients (pts) 

with heavily pretreated leukemia. 

Authors*: Jorge E. Cortes, Javier Pinilla-Ibarz, Philipp D. Le Coutre, Ronald Paquette, Charles Chuah, 

Franck E. Nicolini, Jane Apperley, Hanna Jean Khoury, Moshe Talpaz, Michele Baccarani, Stephanie Lustgarten, 

Frank G. Haluska, Francois Guilhot, Michael W.N. Deininger, Andreas Hochhaus, Timothy P Hughes, 

Neil P. Shah, Hagop M. Kantarjian 


Presentation Date/Time: Monday, June 6: 8:00 - 11:30 Am 


Session: Hematologic Malignancies - Leukemia, Myelodysplastic Syndromes, and Allotransplant 


Shah Research Interests: The Shah lab is interested in advancing targeted therapeutics for hematologic 

malignancies through basic studies of in vitro and in vivo model systems to gain a better understanding of 

the critical vulnerabilities of malignant cells, and through translational/clinical studies of samples obtained 

from patients participating in early phase monotherapy clinical studies to identify, validate and override 

mechanisms of resistance to these agents. 

http://shah.ucsf.edu/ 


67

Presentations 

Pharmacokinetics and pharmacodynamics of gliteritinib in patients 

with relapsed or refractory acute myeloid leukemia. 

Authors*: Catherine Choy Smith, Mark J. Levis, Mark Robert Litzow, Alexander E. Perl, Jessica K. Altman, 

Stan Gill, Geoffrey Yuen, Peter Bonate, Takeshi Kadokura, Angela Joubert James, Charles Liu, Itsuro Nagase, 

Ogert Fisniku, Erkut Bahceci 




Poster Session - Hematologic Malignancies - Leukemia, Myelodysplastic Syndromes, and Allotransplant. 


Smith Research Interests: Our laboratory focuses on identification of therapeutic resistance mechanisms 

and novel treatment strategies for acute myeloid leukemia (AML), particularly AML associated with mutations 

in Fms-like Tyrosine Kinase-3 (FLT3). FLT3 is the most frequently mutated gene in AML, with constitutively 

activating FLT3 internal tandem duplication (ITD) mutations conferring a poor prognosis. We employ 

a prototypical “bedside to bench and back” approach to the problem of cancer drug resistance, founded on 

the belief that the ultimate pathway to improved cancer therapy begins with translational studies that utilize 

samples from patients who have undergone therapy in real time. This strategy allows us to interrogate how 

tumors can evolve under the selective pressure of cancer therapy and allows us to devise ways to circumvent 

these evolutionary adaptations. 

http://cancer.ucsf.edu/people/profiles/smith_catherine.3369 


68

Presentations 

Impact of landmark responses on 3-year (yr) outcomes with ponatinib 

in heavily pretreated CP-CML patients (pts). 

Authors*: Martin C. Müller, Michele Baccarani, Michael W.N. Deininger, Francois Guilhot, Andreas Hochhaus, 

Timothy P. Hughes, Neil P. Shah, Moshe Talpaz, Stephanie Lustgarten, Victor M Rivera, Timothy Piers Clackson, 

Frank G. Haluska, Jorge E. Cortes 




Session: Hematologic Malignancies - Leukemia, Myelodysplastic Syndromes, and Allotransplant 









69

Presentations 

Early molecular response in patients (pts) with chronic myeloid 

leukemia in chronic phase (CML-CP) treated with dasatinib (DAS) or 

imatinib (IM) from DASISION. 

Authors*: Neil P. Shah, Giuseppe Saglio, Andreas Hochhaus, Robyn Bilmes, Li Li, Jorge E. Cortes 



Location: Hall A, poster Board #47 

Poster Session - Hematologic Malignancies - Leukemia, Myelodysplastic Syndromes, and Allotransplant. 








__________________________________________________________________________ 

Clinical, biologic, and outcome differences according to MIBG avidity 

in children with neuroblastoma: A report from the Children’s Oncology 

Group (COG). 

Authors*: Steven G. DuBois, Rajen Mody, Collin Van Ryn, Arlene Naranjo, Susan G. Kreissman, David Baker, 

Marguerite T Parisi, Barry L. Shulkin, John M. Maris, Vandana Batra, Julie R. Park, Katherine K. Matthay, 

Gregory A Yanik 




Session: Pediatric Oncology I 



70

Presentations 

Phase II study of alisertib, irinotecan, and temozolomide in children 

with relapsed and refractory neuroblastoma: A report from the New 

Approaches to Neuroblastoma Therapy (NANT) consortium. 

Authors*: Steven G. DuBois, Araz Marachelian, Elizabeth Fox, Rachel A. Kudgus, Joel M. Reid, 

Susan G. Groshen, Jemily Malvar, Rochelle Bagatell, Lars M. Wagner, John M. Maris, Randall Hawkins, 

Jesse Courtier, Hollie Lai, Fariba Goodarzian, Hiroyuki Shimada, Najee Boucher, Scarlett Czarnecki, 

Denice D Tsao-Wei, Katherine K. Matthay, Yael P. Mosse 




Poster Session: Pediatric Oncology 


__________________________________________________________________________ 

Women informed to screen depending on measures of risk (WISDOM): 

A RCT of personalized vs. annual screening for breast cancer. 

Authors*: Sarah Rosenberg-Wohl, Martin Eklund, Jeffrey Tice, Elad Ziv, Celia Kaplan, Laura Van’t Veer, 

Andrea LaCroix, Lisa Madlensky, Arash Naeim, Neil Wenger, Alexander D. Borowsky, Joshua Fenton, 

Hoda Anton-Culver, Michael Hogarth, Thomas Cink, Susie Brain, Diane Heditsian, Vivian Lee, 

Allison S Fiscalini, Laura Esserman 




Poster Session: Cancer Prevention, Genetics, and Epidemiology 


Esserman Research Interests: Dr. Esserman, surgeon & breast cancer oncology specialist, is the Carol Franc 

Buck Breast Care Center Director and co-leads the Breast Oncology Program. Her research is on improving 

healthcare value through integrating translational science, clinical informatics, systems re-engineering 

& clinical care delivery. In 2005, she received the NCI SPORE Investigator of the Year Award. In 2016 she 

received the Arbuckle Award from Stanford Graduate School of Business for Excellence in Management & 

was named to TIME’s 100 most influential people list. She is PI of the I-SPY TRIAL program, now a model for 

translational research & innovation in clinical trial design. She launched the Athena Breast Health Network to 

follow women from screening through treatment & outcomes, incorporating the latest in molecular testing & 

web-based tools. Athena just launched the WISDOM study to compare personalized vs annual breast cancer 

screening in 100,000 women and to predict who gets what kind of cancer. 

http://profiles.ucsf.edu/laura.esserman 


71

Presentations 

Phase I trial of dual TOR kinase and DNA-PK inhibitor (CC-115) in 

advanced solid and hematologic cancers. 

Authors*: Pamela N. Munster, Amit Mahipal, John J. Nemunaitis, Monica M. Mita, Luis G. Paz-Ares, 

Christophe Massard, Tom Mikkelsen, Cristina Cruz, Dana E. Rathkopf, George R. Blumenschein, 

Manuel Hidalgo, David C. Smith, Barbara Eichhorst, Timothy Francis Cloughesy, Brett Garrick, 

Torsten Trowe, Ellen Filvaroff, Kristen Hege, Johanna C. Bendell 


Presentation Date/Time: Monday, June 6: 8:00 – 11:00AM 


Oral Abstract Session: Developmental Therapeutics - 

Clinical Pharmacology and Experimental Therapeutics 












__________________________________________________________________________ 

FGFR pathway genetic aberrations in cholangiocarcinoma: 

Demographics and experience with targeted therapy. 

Authors*: Apurva Jain, Rachna T. Shroff, Robin Kate Kelley, Ahmed Omar Kaseb, Ying Wang, 

Reham Abdel-Wahab, Daniel H. Ahn, Andrea Grace Bocobo, Funda Meric-Bernstam, Randi Isaacs, 

Tanios S. Bekaii-Saab, Milind M. Javle 




Session: Actionable Mutations Redefined 



72

Presentations 

Can lay health workers achieve the triple aim? Results from the 

Engagement of Patients with Advanced Cancer (EPAC) trial. 

Authors*: Manali I. Patel, VJ Periyakoil, Kate Bundorf, David Thom, Arnold Milstein, Steven M Asch, James Kahn 


Presentation Date/Time: Monday, June 6: 9:45 AM - 12:45 PM 


Session: Health Services Research and Quality of Care 


__________________________________________________________________________ 

Phase I investigation of lenalidomide plus rituximab and outcomes of 

lenalidomide maintenance in recurrent CNS lymphoma. 

Authors*: James L. Rubenstein, Eleanor Fraser, Paul Formaker, James Chi-Chiang Lee, Nianhang Chen, 

Mallory Kock, Wesley Cheung, Xiaomin Wang, Pamela N. Munster, Bertil Damato 




Oral Abstract Session: Hematologic Malignancies - Lymphoma and Chronic Lymphocytic Leukemia 


Rubenstein Research Interests: Our goals are to develop innovative therapies that are based upon the 

biological properties of cancer, that have both enhanced efficacy as well as less toxicity compared to 

established interventions. Our major interests are: 1) identification of genetic factors associated with 

therapeutic resistance; 2) molecular basis of tumor cell tropism within the brain; 3) elucidation of the tumor 

immune microenvironment. We are simultaneously engaged in leading phase I and II trials , in correlative 

studies involving novel immunotherapeutic strategies, in the development of novel preclinical models that 

facilitate both insights into disease mechanisms as well as the testing of novel therapeutic strategies. 

https://bms.ucsf.edu/directory/faculty/james-rubenstein-md-phd 


73

Presentations 

Abexinostat (ABX) as a means to reverse pazopanib (PAZ) resistance: 

A phase 1 study in advanced solid tumor malignancies. 

Authors*: Rahul Raj Aggarwal, Scott Thomas, Jennifer A. Grabowsky, Armand Harb, Jim Leng, 

Anne Reinert, Ilaria Mastroserio, Thach-Giao Truong, Pamela N. Munster 



Location: Arie Crown Theater 

Poster Disussion Session: Developmental Therapeutics—Clinical Pharmacology and Experimental Therapeutics 












__________________________________________________________________________ 

Risk Reduction Through Lifestyle Modifications 

Authors*: Michelle E. Melisko 

Abstract #: 



Education Session: Breast Cancer Survivorship: Strategies for Optimal Care 

Citation: 


74

Presentations 

Medical Management of Low-Grade Gliomas 

Authors*: Susan Marina Chang 

Abstract #: 

Presentation Date/Time: Monday, June 6: 11:50 AM - 12:10 PM 


Education Session: Treatment of Low-Grade Gliomas in the Era of Genomic Medicine 

Citation: 

Chang Research Interests: My research interest is in the development of novel therapies for patients with brain 

tumors, as well as the assessment of novel imaging biomarkers in the management of patients. My research 

seeks to integrate advances in physiologic and metabolic imaging with tissue biomarkers in order to optimize 

the management of patients with glioblastoma (GBM). My clinical research evaluates a wide spectrum of 

therapeutic interventions that span chemotherapy, targeted agents, immunotherapy and convection enhanced 

delivery of novel agents. I am the site PI of an NIH-funded adult brain tumor consortium and am a member 

of the Brain Malignancy Steering Committee and the Developmental Therapeutics Study Section at the NIH. I 

am the program leader for the Neuro-Oncology Program at the HDFCCC. I am the clinical co-PI for the UCSF 

Brain Tumor SPORE and a co-Leader of a SPORE Project evaluating the role of physiologic imaging in the 

determination of malignant progression of low-grade glioma. 



75

Presentations 

Programmed death-ligand 1 (PD-L1) characterization of circulating tumor 

cells (CTCs) in muscle invasive and metastatic bladder cancer patients. 

Authors*: Archana Anantharaman, Terence W. Friedlander, David Lu, Rachel Krupa, Gayatri Premasekharan, 

Jeffrey Hough, Matthew Edwards, Ryon Graf, Adam Jendrisak, Jessica Louw, Lyndsey Dugan, 

Dena C. Marrinucci, Ryan Vance Dittamore, Pamela Paris 


Presentation Date/Time: Monday, June 6: 1:00 - 4:30 PM 


Poster Session: Genitourinary (Nonprostate) Cancer 


Paris Research Interests: My background is in biophysical chemistry. My research focuses on biomarker 

discovery. As a UCSF Prostate SPORE program Research Fellow, I discovered a DNA-based biomarker set to 

assess risk of recurrence after primary treatment. My landmark paper in the American Journal of Pathology 

set the stage for the use of formalin-fixed paraffin-embedded (FFPE) prostate cancer tissue with microarrays 

for copy-number assessment. I was the first to demonstrate FFPE prostate biopsy tissue could be profiled on 

high-resolution microarrays. As Professor, I work as a translational researcher in prostate cancer, both in solid 

tumor and circulating biomarkers. I helped move the circulating tumor cell (CTC) field beyond enumeration 

and was the first to genomically profile prostate cancer CTCs. Recently, I have applied similar approaches to 

identify clinically relevant bladder cancer biomarkers. My research goal is to identify predictive and prognostic 

biomarkers to aid in clinical cancer decision-making. 

http://urology.ucsf.edu/research/cancer/cancer-research-programs/paris-laboratory 


76

Presentations 

Prospective evaluation of circulating cell-free DNA sequencing in 

patients with metastatic renal cell carcinoma treated with pazopanib 

plus abexinostat. 

Authors*: Jim Leng, Armand Harb, Kamran Abri, Ilaria Mastroserio, Anne Reinert, Jennifer A. Grabowsky, 

Charles J. Ryan, Terence W. Friedlander, Amy M. Lin, Richard Burnham Lanman, Kimberly C. Banks, 

Rahul Raj Aggarwal, Pamela N. Munster 











and molecular imaging for patients with advanced stage cancer. My basic research interest is centered on the 

role of epigenetic modification in therapy resistance in breast cancer and epigenetic priming. In addition to 

studying basic mechanisms of hormone therapy resistance, we have shown that epigenetic modification plays 

a crucial role in the hormonal regulation and carcinogenesis of breast cancer. 



77

Presentations 

Phase 1 study of CB-839, a small molecule inhibitor of glutaminase 

(GLS), alone and in combination with everolimus (E) in patients (pts) 

with renal cell cancer (RCC). 

Authors*: Funda Meric-Bernstam, Nizar M. Tannir, James Walter Mier, Angela DeMichele, Melinda L. Telli, 

Alice C. Fan, Pamela N. Munster, Richard D. Carvajal, Keith W. Orford, Mark K. Bennett, Othon Iliopoulos, 

Taofeek Kunle Owonikoko, Manish R. Patel, Rana McKay, Jeffrey R. Infante, Martin Henner Voss, 

James J. Harding 
















__________________________________________________________________________ 

ADXS11-001 immunotherapy in squamous or non-squamous 

persistent/recurrent metastatic cervical cancer: Results from 

stage I of the phase II GOG/NRG0265 study. 

Authors*: Warner King Huh, Don S. Dizon, Matthew A. Powell, Charles A. Leath, Lisa Michelle Landrum, 

Edward Tanner, Robert Higgins, Stefanie M. Ueda, Michael T. McHale, Bradley J. Monk, Carol Aghajanian 







78

Presentations 

A phase II randomized, double-blind trial of a polyvalent vaccine-KLH 

conjugate (NSC 748933 IND# 14384) + OPT-821 versus OPT-821 in 

patients with epithelial ovarian (EOC), fallopian tube, or peritoneal 

cancer who are in second or third complete remission. 

Authors*: Paul Sabbatini, Lee-may Chen, Joseph A. Lucci, Kian Behbakht, Nicola M. Spirtos, Carolyn Muller, 

Benedict B. Benigno, Matthew A. Powell, Emily Berry, Krishnansu Sujata Tewari, Parviz Hanjani, Wei Deng, 

Heather A. Lankes, Carol Aghajanian 






__________________________________________________________________________ 

Pembrolizumab in advanced endometrial cancer: Preliminary results 

from the phase Ib KEYNOTE-028 study. 

Authors*: Patrick Alexander Ott, Yung-Jue Bang, Dominique Berton-Rigaud, Elena Elez, Michael J. Pishvaian, 

Hope S. Rugo, Igor Puzanov, Mark Aloysuis Morgan, Janice M. Mehnert, Kyaw Lwin Aung, Marion Carrigan, 

Sanatan Saraf, Mei Chen, Jean-Charles Soria 


















79

Presentations 

Impact of age and comorbidity on treatment of non-small cell lung 

cancer (NSCLC) recurrence (AFT-03). 

Authors*: Melisa L. Wong, Timothy L. McMurry, George J. Stukenborg, Amanda B. Francescatti, 

Jessica R. Schumacher, Louise C. Walter, Benjamin D. Kozower 




Poster Session: Patient and Survivor Care 


Walter Research Interests: Dr. Walter is a clinician-researcher who is a national leader in evaluating the 

real-world risks and benefits of cancer screening in older patients. Dr. Walter joined the UCSF faculty 

in July 2001, and she is a geriatrician at the San Francisco VA Medical Center. She has developed novel 

methodology demonstrating the fundamental importance of life expectancy rather than age in determining 

benefits and risks of screening. Virtually every cancer screening guideline cites her research. In addition, 

Dr. Walter led a series of seminal studies demonstrating decisions to screen older adults for cancer are often 

dictated more by age than health such that many patients in poor health continue to undergo screening 

while many healthy older patients fail to get screened. Also, she discovered that cancer screening frequently 

leads to significant harms without benefit in patients in poor health and developed a taxonomy and 

quantification of screening harms. 

http://cancer.ucsf.edu/people/profiles/walter_louise.3728 


80

Presentations 

Early, molecular detection of cancer utilizing circulating cell-free DNA 

assay with ultra high accuracy and sensitivity. 

Authors*: Stefanie Mortimer, Katharine Dilger, Diana Abdueva, Darya Chudova, Ankit Sarin, 

Chloe Evelyn Atreya, Jim Leng, Jeeyun Lee, Helmy Eltoukhy, Pamela N. Munster, AmirAli Talasaz 




Poster Session: Tumor Biology 


__________________________________________________________________________ 

Development and safety of a novel, irreversibly-binding PSMAtargeted 

prostate cancer radiodiagnostic. 

Authors*: Elizabeth Whalley, Clifford Berkman, Henry Vanbrocklin, Beatrice Langton-Webster 




Session: Tumor Biology 


VanBrocklin Research Interests: The VanBrocklin laboratory focuses on developing nuclear imaging 

agents targeting cell surface proteins (receptors, enzymes and transporters) and signalling pathways and 

mechanisms by PET and SPECT imaging. We have developed imaging agents covering a broad range of 

molecular motifs from small molecules, antibodies, antibody fragments (e.g., Fabs, scFv, and diabodies), 

and aptamers, to proteins and peptides. We synthesize, evaluate and validate tracer mechanisms of 

localization and retention at the target site. We utilize in vitro and in vivo model systems to test the probes 

and interpret the data collected from these systems to determine their utility for research or as a future 

diagnostic. We have successfully translated many of these tracers into humans for drug development or 

evaluation as future diagnostics. 

http://cancer.ucsf.edu/people/profiles/vanbrocklin_henry.3696 


81

Presentations 

Correlation between local 18F-fluorodeoxyglucose PET/CT and 

T-cell exhaustion for predicting treatment response in patients with 

advanced melanoma treated with checkpoint inhibitor mono-therapy. 

Authors*: Miguel Hernandez Pampaloni, Lorenzo Nardo, Alain Patrick Algazi, Katy K. Tsai, Kimberly 

Loo, Luca Facchetti, Susana Ortiz-Urda, Adil Daud 
















__________________________________________________________________________ 

CHK1 inhibition as a therapeutic approach in KRAS mutated and 

squamous cell carcinoma NSCLC patients. 

Authors*: Daniela Morales-Espinosa, Silvia García-Román, Miguel Angel Molina-Vila, Ana Gimenez Capitan, 

Jordi Bertran-Alamillo, Pedro Mendez, Santiago Viteri Ramirez, Niki Karachaliou, Rafael Rosell 







82

Presentations 

Metastatic melanoma, glioblastoma and high-grade extrapulmonary 

neuroendocrine carcinomas (NECs) as novel indications for 

rovalpituzumab tesirine: A delta-like protein 3 (DLL3)-targeted 

antibody-drug conjugate (ADC). 

Authors*: Stanford L. Peng, Laura Saunders, Sheila Bheddah, Sam Williams, Rahul Raj Aggarwal, 

Jill E. Shea, Eun Y Lee, Jiaoti Huang, Allison J Zemek, Teri A. Longacre, Douglas Wilmot Ball, 

Courtney L. Scaife, Barry Nelkin, Lowell Brian Anthony, Pamela L. Kunz, Eric Jay Small, Scott Dylla 






Small Research Interests: The Stand Up To Cancer Dream Team led by Dr. Eric Small is exploring the idea 

that resistance to hormonal therapy occurs as a result of the prostate cancer cells using common cellular 

responses - what the Dream Team calls “adaptive pathways” - to escape the current prostate cancer 

therapies. They believe that, by identifying these pathways and inhibiting them, they will be able to overcome 

treatment resistance and profoundly improve the care of men affected by this fatal disease. This team is a six 

institution consortium to include UC Los Angeles, UC Davis, UC Santa Cruz, University of British Columbia, 

Oregon Health and Sciences University, with UCSF as the lead administrative site. 



83

Presentations 

PALOMA-2: Primary results from a phase III trial of palbociclib (P) with 

letrozole (L) compared with letrozole alone in postmenopausal women 

with ER+/HER2– advanced breast cancer (ABC). 

Authors*: Richard S. Finn, Miguel Martin, Hope S. Rugo, Stephen E. Jones, Seock-Ah Im, Karen A. Gelmon, 

Nadia Harbeck, Oleg N. Lipatov, Janice Maria Walshe, Stacy L. Moulder, Eric Roland Gauthier, Dongrui (Ray) Lu, 

Sophia Randolph, Véronique Diéras, Dennis J. Slamon 







clinical trials focusing on combining novel targeted therapeutics to improve the treatment of both early & 

late stage breast cancer (BC). She also works on studies to improve supportive care for early & late stage 





negative working group. She is on the novel agents committee for the neoadjuvant multi-center I SPY2 

trial. At UCSF, Dr. Rugo runs the Breast Forum, a bimonthly educational session for breast cancer patients, 

families & friends from throughout the bay area. 



84

Presentations 

Three-year overall survival for patients with advanced melanoma 

treated with pembrolizumab in KEYNOTE-001. 

Authors*: Caroline Robert, Antoni Ribas, Omid Hamid, Adil Daud, Jedd D. Wolchok, Anthony M. Joshua, 

Wen-Jen Hwu, Jeffrey S. Weber, Tara C. Gangadhar, Richard Wayne Joseph, Roxana Stefania Dronca, 

Amita Patnaik, Hassane M. Zarour, Richard Kefford, Peter Hersey, Xiaoyun Li, Scott J. Diede, 

Scot Ebbinghaus, F. Stephen Hodi 

















85

Presentations 

Pembrolizumab versus ipilimumab for advanced melanoma: Final 

overall survival analysis of KEYNOTE-006. 

Authors*: Jacob Schachter, Antoni Ribas, Georgina V. Long, Ana Arance, Jean Jacques Grob, Laurent Mortier, 

Adil Daud, Matteo S. Carlino, Catriona M. McNeil, Michal Lotem, James M. G. Larkin, Paul Lorigan, 

Bart Neyns, Christian U. Blank, Teresa M. Petrella, Omid Hamid, Honghong Zhou, Scot Ebbinghaus, 

Nageatte Ibrahim, Caroline Robert 

















86

Presentations 

Heritage: A phase III safety and efficacy trial of the proposed 

trastuzumab biosimilar Myl-1401O versus herceptin. 

Authors*: Hope S. Rugo, Abhijit Barve, Cornelius F. Waller, Miguel Hernandez-Bronchud, Jay Herson, 

Jinyu Yuan, Alexey Manikhas, Igor Bondarenko, Guzel Mukhametshina, Gia Nemsadze, Joseph D. Parra, 

Maria Luisa T. Abesamis Tiambeng, Kakhaber Baramidze, Charuwan Akewanlop, Ihor Vynnychenko, 

Virote Sriuranpong, Gopichand Manillapalli, Sirshendu Ray, Eduardo Patricio Yanez Ruiz, Eduardo J. Pennella 

Abstract #: LBA503 



Oral Abstract Session: Breast Cancer - HER2/ER 

Citation: J Clin Oncol 34, 2016 (suppl; abstr LBA503) 












__________________________________________________________________________ 

Efficacy and safety of programmed death receptor-1 (PD-1) blockade in 

metastatic uveal melanoma (UM). 

Authors*: Katy K. Tsai, Alexander Noor Shoushtari, Rodrigo Ramella Munhoz, Zeynep Eroglu, Josep M. Piulats, 

Patrick Alexander Ott, Douglas Buckner Johnson, Jimmy Hwang, Adil Daud, Jeffrey Alan Sosman, 

Richard D. Carvajal, Bartosz Chmielowski, Michael Andrew Postow, Jeffrey S. Weber, Ryan J. Sullivan, 

Alain Patrick Algazi 


Presentation Date/Time: Monday, June 6: 1:15 – 4:15PM 


Oral Abstract Session: Melanoma/Skin Cancers 



87

Presentations 

Beyond Hormone Therapy for Breast Cancer: 

Who Needs Targeted Agents? 

Authors*: Hope S. Rugo 

Abstract #: 



Education Session: Targeted Therapies in Hormone Receptor-Positive Breast Cancer 

Citation: 












__________________________________________________________________________ 

Emerging Insights Into Molecular Profiling 

Authors*: Wolfgang Michael Korn 

Abstract #: 



Poster Discussion Session: Tumor Biology 

Citation: 

Korn Research Interests: Dr. Korn is a physician-scientist focused on the science and management of 

gastrointestinal cancers. Furthermore, he is the leader of the UCSF Molecular Oncology Initiative and 

founding Chair of the UCSF Molecular Tumor Board. He is principal investigator of clinical trials exploring 

new treatments for gastrointestinal cancers and conducts molecularly driven, disease-independent basket 

trials. His laboratory conducts research aimed at developing combination therapies for gastrointestinal 

cancers, based on the analysis of signal transduction and DNA repair pathways. 

http://cancer.ucsf.edu/gi/michael-korn 


88

Presentations 

Determining barriers to effective data sharing in cancer genomic 

sequencing initiatives: A Global Alliance for Genomics and Health 

(GA4GH) survey. 

Authors*: Jeremy Howard Lewin, Daniel J Vis, Emile E. Voest, Rachel Liao, Petra M Nederlof, Barbara A. Conley, 

David B. Solit, Christopher L. Corless, Paulo V Campregher, Vanessa Tyrell, George Chong, Michael Watson, 

Sun Young Rha, Tim Maughan, Mark Caulfield, Vladimir Lazar, Laura Esserman, Charles L. Sawyers, 

Lillian L. Siu, Mark Lawler 


Presentation Date/Time: Tuesday, June 7: 8:00 - 11:00 AM 
















89

Presentations 

A phase Ib dose escalation trial of isatuximab (SAR650984, anti-CD38 

mAb) plus lenalidomide and dexamethasone (Len/Dex) in relapsed/ 

refractory multiple myeloma (RRMM): Interim results from two new 

dose cohorts. 

Authors*: Ravi Vij, Nikoletta Lendvai, Thomas G. Martin, Rachid C. Baz, Frank Campana, Florent Mazuir, 

Eric Charpentier, Don M. Benson 


Presentation Date/Time: Tuesday, June 7: 9:45 - 11:15 AM 


Session: Novel Combination Therapies in Myeloma 


Martin Research Interests: A leading expert in hematology-oncology, Dr. Thomas Martin is the associate 

director of the Myeloma Institute and director of the Unrelated Donor Transplantation Program for adults at 

UCSF Medical Center. He is also clinical research director of hematologic malignancies, or blood cancers, 

at the UCSF Helen Diller Family Comprehensive Cancer Center. His research interests include developing 

treatments for myeloma and leukemia as well as expanding the use of bone marrow transplants. He has 

a special interest in umbilical cord blood transplants and is involved in efforts to improve the outcomes 

following unrelated donor transplants. 

http://cancer.ucsf.edu/research/multiple-myeloma/mmti/mmti_team#martin 


90

Presentations 

Controversies in Local Therapy: Surgery and Radiation 

Authors*: Laura Esserman 

Abstract #: 

Presentation Date/Time: Tuesday, June 7: 11:50 AM - 12:10 PM 


Education Session: Less is More: A Multidisciplinary Conversation on Treatment Options 

Citation: 













91

Presentations 

ERASE: Elimination of recurring artifacts and stochastic errors: An 

NGS analysis approach and its application to liquid biopsy samples. 

Authors*: Nicholas Kamps-Hughes, Tony Tran, Reynolds Brobey, Robert J. Amato, Ajjai Shivaram Alva, 

Pamela Paris, Terence W. Friedlander, Gayatri Premasekharan, Cristian Ionescu-Zanetti 

Abstract #: e13002 

Presentation Date/Time: Publication Only 

Location: Publication Only 

Session: Publication Only 

Citation: J Clin Oncol 34, 2016 (suppl; abstr e13002) 

Paris Research Interests: My background is in biophysical chemistry. My research focuses on biomarker 

discovery. As a UCSF Prostate SPORE program Research Fellow, I discovered a DNA-based biomarker set to 

assess risk of recurrence after primary treatment. My landmark paper in the American Journal of Pathology 

set the stage for the use of formalin-fixed paraffin-embedded (FFPE) prostate cancer tissue with microarrays 

for copy-number assessment. I was the first to demonstrate FFPE prostate biopsy tissue could be profiled on 

high-resolution microarrays. As Professor, I work as a translational researcher in prostate cancer, both in solid 

tumor and circulating biomarkers. I helped move the circulating tumor cell (CTC) field beyond enumeration 

and was the first to genomically profile prostate cancer CTCs. Recently, I have applied similar approaches to 

identify clinically relevant bladder cancer biomarkers. My research goal is to identify predictive and prognostic 

biomarkers to aid in clinical cancer decision-making. 

http://urology.ucsf.edu/research/cancer/cancer-research-programs/paris-laboratory 

__________________________________________________________________________ 

The WISDOM study pilot: Evaluating a preference-tolerant RCT of riskbased 

vs. annual breast cancer screening. 

Authors*: Sarah Theiner, Celia Kaplan, Setareh Sarrafan, Julissa Cabrera, Sarah Dilys Sawyer, 

April S Liang, Sarah Rosenberg-Wohl, Miya Frick, Emily Claire Wong, Jeffrey Tice, Elad Ziv, 

Alexander D. Borowsky, Hoda Anton-Culver, Arash Naeim, Andrea LaCroix, Thomas Cink, Laura Esserman, 

Laura Van’t Veer, Allison S Fiscalini 







92

Presentations 

A pharmacodynamic study of pre-prostatectomy buparlisib in men 

with high-risk, localized prostate cancer. 

Authors*: Archana Anantharaman, Hao Gia Nguyen, Matthew R. Cooperberg, Maxwell V. Meng, 

Peter Carroll, Terence W. Friedlander, Li Zhang, Miles Thomas, Phillip G. Febbo, Felix Yi-Chung Feng, 

Charles J. Ryan, Won Kim 






__________________________________________________________________________ 

Second-line chemotherapy (CTx) outcomes in advanced biliary 

cancers (ABC): A retrospective multicenter analysis. 

Authors*: Laura Williams Goff, Maeve Aine Lowery, Emmet Jordan, Rui Wang, Andrea Grace Bocobo, 

Joanne F. Chou, Eileen Mary O’Reilly, James J. Harding, Nancy E. Kemeny, Marinela Capanu, 

Ann C. Griffin, Joseph P. McGuire, Alan P. Venook, Ghassan K. Abou-Alfa, Robin Kate Kelley 







93

Presentations 

Next-generation sequencing (NGS) in an advanced hepatocellular 

carcinoma (HCC) cohort: Analysis of common mutations, clinical 

covariates, and overall survival (OS). 

Authors*: Robin Kate Kelley, Paige M. Bracci, John Dozier Gordan, Kimberley Evason, Nancy M. Joseph, 

Andrea Grace Bocobo, Blake K. Rosenthal, Hubert J. Stoppler, Halla Sayed Nimeiri, Alan P. Venook 






Venook Research Interests: Dr. Alan Venook is a nationally renowned expert in colorectal and liver cancers 

at the UCSF Helen Diller Family Comprehensive Cancer Center. He is highly regarded for his expertise 

in the effective use of the newest approaches and therapies to the treatment of colorectal cancer, as well 

treating primary and metastatic tumors to the liver. Dr. Venook has chaired and/or authored six major 

studies within the cooperative groups and he now Chairs the GI Committee of the Alliance for Clinical Trials 

in Oncology (formerly CALGB.) 



94

Presentations 

Final results of a phase Ib dose-escalation study of PRI-724, a CBP/ 

beta-catenin modulator, plus gemcitabine (GEM) in patients with 

advanced pancreatic adenocarcinoma (APC) as second-line therapy 

after FOLFIRINOX or FOLFOX. 

Authors*: Andrew H. Ko, E. Gabriela Chiorean, Eunice Lee Kwak, Heinz-Josef Lenz, Paul I. Nadler, 

Debra L. Wood, Masamoto Fujimori, Tetsuhi Inada, Hiroyuki Kouji, Robert R. McWilliams 
















__________________________________________________________________________ 

Microarray-based tumor ploidy and its association with lymph node 

involvement in bladder cancer. 

Authors*: Karla Lindquist, Thomas Sanford, Maxwell V. Meng, Pamela Paris, Sima P. Porten 







95

Presentations 

Treatment patterns for metastatic castration-resistant prostate cancer 

(mCRPC) in oncology (ONC) urology (URO) practices: Data from the 

PROCEED registry. 

Authors*: Nicholas J. Vogelzang, Andrew J. Armstrong, Celestia S. Higano, A. Oliver Sartor, 

Christopher Michael Pieczonka, Raoul S. Concepcion, Ronald F. Tutrone, Carl A. Olsson, James L. Bailen, 

David F. Penson, Nancy N. Chang, Jennifer Susan LIll, Robert Claude Tyler, Matthew R. Cooperberg 






__________________________________________________________________________ 

Dehydroepiandrosterone (DHEA) in metastatic castration-resistant 

prostate cancer (mCRPC): Preliminary results from the SU2C/PCF/ 

AACR West Coast Dream Team (WCDT) 

Authors*: Won Kim, Charles J. Ryan, Li Zhang, Jack Youngren, John Wilton, Joshi J. Alumkal, 

Tomasz M. Beer, Robert Baertsch, Josh Stuart, Kim N. Chi, Martin Gleave, Matthew Rettig, 

Robert Evan Reiter, Primo Lara, Christopher P. Evans, Eric Jay Small 















96

Presentations 

Comparative performance of surveillance mammography and breast 

MRI in women with a history of breast cancer. 

Authors*: Karen Wernli, Laura E Ichikawa, Karla Kerlikowske, Mary Bush, Dianne Johnson, Diana SM Buist, 

Susan Brandzel, Wendy DeMartini, Louise Henderson, Lariss Nekhlyudov, Tracy Onega, Brian Sprague, 

Diana Miglioretti 






Kerlikowske Research Interests: My lab focuses on breast imaging and the epidemiology of invasive breast 

cancer, DCIS and breast density, and risk prediction models for invasive breast cancer. We have developed 

cohorts of women at risk for invasive breast cancer and DCIS and developed comprehensive databases 

that include breast imaging, pathologic, clinical, biomarker, and risk factor data, as well as follow-up for 

subsequent disease and death. 

http://cancer.ucsf.edu/people/profiles/kerlikowske_karla.3457 


97

Presentations 

Enabling a paradigm shift: A preference-tolerant RCT of personalized 

vs. annual screening for breast cancer. 

Authors*: Sarah Rosenberg-Wohl, Prihatha Narasimmaraj, Allison S Fiscalini, Karyn DiGiorgio, Lisa Latts, 

Marcus Thygeson, Martin Eklund, Jason Connor, Kristine Broglio, Jeffrey Tice, MaryBeth Kramer, 

Andrea LaCroix, Robert A. Hiatt, Barbara A. Parker, Tracy M. Layton, Laura Esserman 

















__________________________________________________________________________ 

Non-invasive detection of crizotinib resistance in ALK-rearranged lung 

adenocarcinoma directs treatment with next-generation ALK inhibitors. 

Authors*: Nnamdi Ihuegbu, Kimberly C. Banks, Stephen R Fairclough, Oliver A. Zill, Darya Chudova, 

Richard Burnham Lanman, Collin M. Blakely 







98

Presentations 

Identification of symptom clusters by occurrence and severity in lung 

cancer patients receiving chemotherapy. 

Authors*: Melisa L. Wong, Bruce A. Cooper, Judy Mastick, Steven M. Paul, Christine Miaskowski 






__________________________________________________________________________ 

Circulating tumor DNA sequencing to reveal the genomic complexity 

of advanced EGFR-mutant lung adenocarcinoma. 

Authors*: Collin M. Blakely, Kimberly C. Banks, Richard Burnham Lanman, Jonathan Riess, Philip C. Mack, 

Trever Grant Bivona 






Bivona Research Interests: Our team uses the tools of precision medicine to improve the molecular 

diagnosis and targeted therapy of patients with solid cancers, including lung cancer. Our program focuses 

on identifying and functionally characterizing the molecular drivers of tumor growth in individual patients. 

We study patient samples and clinical data to identify novel potential drivers of tumor initiation, progression, 

and therapy resistance. We functionally annotate the putative molecular drivers using an integrated approach 

of genetic and pharmacologic tools. This precision approach to understanding the molecular pathogenesis 

of lung cancer (and other cancers) has led to the discovery of new biomarkers and targets that provide 

rationale for novel clinical trials we are launching to improve patient survival. 

http://www.bivonalab.net/ 


99

Presentations 

Functional annotation of cancer driver genes in breast cancer patientderived 

xenografts to identify a novel target for PARP inhibitors. 

Authors*: Xiaosong Zhang, Meng Li, Olga Momcilovic, Andrew Beardsley, Roman Camarda, Andrei Goga 






Goga Research Interests: Tumor cells are driven to proliferate, alter their metabolism, and deregulate 

cell death pathways by oncogene over-expression or the loss of tumor-suppressor genes. We seek to 

understand how oncogenes alter these pathways using cell-based and transgenic animal models. We are 

especially interested in how the prototypical oncogene Myc acts in diverse tumor types, including amongst 

the most aggressive breast and liver cancers and lymphomas. Myc has also been postulated to drive a 

‘stem cell like’ gene expression pattern which may regulate tumor stem cell function. We seek to elucidate 

the genes and pathways that are indispensable for Myc function, and thus uncover potential ‘achilles heels’ 

of tumor cells. Our ultimate goal is to translate our basic discoveries to novel cancer therapeutics. 

http://oncogenes.net/Goga_Lab/Home.html 


100

UCSF HELEN DILLER FAMILY COMPREHENSIVE CANCER CENTER

Create successful ePaper yourself

Delete template?

Save as template?